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ISG15 Discovery 
The study of ubiquitin conjugation has played a key role in furthering our understanding 
of the mechanisms by which proteins and biological pathways can be regulated at a post-
translational level.  Ubiquitin is an 8.5-kD protein originally named for the nearly universal 
cross-immunoreactivity between the ubiquitin homologs throughout eukaryotic species. 
Ubiquitin covalently conjugates to target proteins forming an isopeptide bond between its C-
terminal glycine and the amine groups of lysine residues in target proteins.  Ubiquitination 
occurs through an ATP dependent enzymatic pathway consisting of an E1 activating enzyme, an 
E2 conjugating enzyme, and an E3 ligase
1
.  One of the first functions ascribed to ubiquitin 
conjugation was the targeting of ubiquitinated proteins for proteasomal degradation
2
.  However 
ubiquitin has since been shown to affect many cellular processes independent of proteasomal 
degradation, including the regulation of vesicular trafficking, signaling pathways, and DNA 
damage repair
3
.   
Following the discovery of ubiquitin, numerous other proteins were identified that also 
covalently conjugate to target proteins through an enzymatic pathway similar to that of ubiquitin 
conjugation
4
.  These ubiquitin-like modifiers share limited sequence homology to ubiquitin but 
contain one or more domains that adopt a beta-grasp structure similar to that of ubiquitin.  The 
first ubiquitin-like protein to be discovered was interferon stimulated gene 15 (ISG15).  ISG15 
was discovered independently by two different laboratories.  Korant et al. identified ISG15 
during a study characterizing proteins induced by type I interferons (IFN)
5
.  Protein lysates from 
Daudi cells stimulated with IFN were analyzed by 2-D gel electrophoresis at different times after 
stimulation.   ISG15 was found to be rapidly and robustly induced after IFN stimulation.  ISG15 
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was also identified by a group evaluating how the pool of ubiquitin conjugates is affected by 
viral infection
6
.  This study revealed that infecting A549 cells with encephalomyocarditis virus 
induced a 15-kD protein which cross-reacted with an antibody raised against ubiquitin.  
Consequently, ISG15 was originally named ubiquitin cross-reactive protein by this group.  
Subsequent cloning and characterization of ISG15 revealed that it contained two ubiquitin-like 
domains, each with approximately 30% amino acid sequence homology to ubiquitin
6; 7; 8
.  The 
structural similarity of ubiquitin and the ubiquitin-like domains of ISG15 was later confirmed 
when the crystal structure of ISG15 was solved 
9
.  Given the known regulatory potential of 
ubiquitin-like modifiers and the importance of type I IFN during viral infection, there has been 
great interest in understanding how ISG15 might regulate the immune response and virus 
replication. 
 
ISG15 Conjugation 
ISG15 forms conjugates with a diverse pool of target proteins in a process referred to as 
ISGylation.  ISGylation occurs through a series enzymatic reactions similar to the ubiquitin 
conjugation pathway (Figure 1.1).  ISG15 is encoded and expressed as a 17-kD precursor protein 
that is immediately proteolytically processed at its C-terminus to expose a C-terminal LRLRGG 
amino acid sequence, identical to the C-terminal sequence of ubiquitin
10
.  The cognate ISG15 E1 
activating enzyme, UbE1L, initiates the ISG15 conjugation enzymatic pathway by forming a 
thioester bond between the C-terminal glycine of ISG15 and a cysteine residue of UbE1L
11; 12
.  
UbE1L is the only known E1 enzyme for ISG15, and it appears to be specific for ISG15 as it has 
not formed thioester bonds with other tested ubiquitin-like modifiers
11; 13
.  Confirmation of the 
 4 
importance of UbE1L in this pathway has come from the analysis of mice deficient in UbE1L.  
These mice express unconjugated ISG15 but do not form ISG15 conjugates
14
.  Once primed by 
UbE1L, ISG15 is then transferred to a cysteine residue of an E2 conjugating enzyme.  siRNA 
knockdown of UbcH8 in human cells, and UbcM8 in mouse cells, results in nearly complete loss 
of ISG15 conjugate formation, suggesting that UbcH8 and UbcM8 serve as the predominant E2 
enzymes in the ISG15 conjugation system
15; 16
.  Additional experiments evaluating whether other 
proteins may serve as ISG15 E2 enzymes have found the transfer of ISG15 to UbcH5 and to 
UbcH7, the closest homologs of UbcH8, to be highly unfavorable
12; 17
.  Finally, an E3 ligase 
facilitates the conjugation of ISG15 to target proteins.  HERC5, HHARI, and Efp (TRIM25) 
have all been demonstrated capable of acting as E3 ligases for ISG15
18; 19; 20; 21
.  However, while 
HHARI and Efp have been shown to act as E3 ligases for specific target proteins, siRNA 
knockdown of the HECT E3 ligase HERC5 was shown to abrogate nearly all ISG15 conjugate 
formation, suggesting that it is the predominant E3 ligase for ISG15.  Knockdown studies in 
mouse cells have similarly demonstrated that HERC6 is the predominant ISG15 E3 ligase in 
mice
22; 23; 24
.   
In an elegant study of ISG15 conjugation specificity, it was shown that almost any 
protein inserted into an expression vector can be ISGylated in a manner that appears to require 
little sequence specificity
25
.  Truncation of target proteins leads to alteration in the ISGylation 
profile of the protein, further suggesting that the specificity of ISG15 conjugation is not strictly 
determined by the local amino acid sequence environment of its lysine residues.  This study 
showed that ISGylation targets newly translated proteins, and this appears to be mediated in part 
by the interaction of HERC5 with polysomes.  Thus the specificity of ISG15 is in part derived 
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from the temporal expression of target proteins.  How, or if, ISG15 might discriminate between 
proteins within the pool of actively translated proteins is unclear. 
Enzymes capable of deconjugating ISG15 have also been identified.  UBP43, also known 
as USP18, has been shown to deconjugate ISG15 from ISGylated target proteins
26
.  The 
biological function of UBP43 and the effect of increasing ISG15 conjugation were initially 
evaluated both in vitro and in UBP43 deficient mice
26; 27; 28
.  However, the interpretations of 
these studies have been complicated by the fact that UBP43 has been found to bind to the 
interferon / receptor (IFNAR) 2 and inhibit IFN signaling independent of its deconjugating 
activity
29; 30
.  USP2, USP5, USP13, USP14 have also been shown to cleave peptide fused to the 
C-terminus of ISG15, however, further studies are needed to determine whether they can 
deconjugate ISG15 from ISGylated proteins and to understand what biological roles they may 
play in the regulation of ISGylation
31
.  Characterization of these ISG15 deconjugases could 
advance our understanding of ISGylation, as deubiquitinating enzymes have been found to play 
an important role in ubiquitin mediated regulation
32
. 
Proteomic studies have identified hundreds of proteins that are either ISGylated or 
interact with ISG15 after IFN stimulation
33; 34
.  These potential target proteins are involved in all 
aspects of cellular biology.  The functional consequence of ISGylation is still not well 
understood.  Proteasome inhibition has been reported to increase the pool of ISG15 conjugates 
but does so by means of de novo conjugate formation, not inhibition of conjugate degradation
35
.  
In fact, there is no evidence that ISGylation results in the proteasome mediated degradation of 
target proteins.  One of the challenges of studying ISG15 has been that for every target protein 
studied, only a small fraction of the total pool of target protein is actually modified by ISG15.  
This phenomenon is also observed with the small ubiquitin-like modifier (SUMO).  SUMO 
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modification is thought to be highly dynamic, but transient modification of transcription factors 
can lead to long lasting downstream consequences through chromatin remodeling or recruitment 
of inhibitory complexes
36
.  Whether a similar dynamic effect might mediate the functionality of 
ISGylation has yet to be determined. 
Though the biochemical conjugation of ISG15 parallels that of ubiquitination, there are 
several notable differences between the conjugation systems (Figure 1.1).  Firstly, like ISG15 
itself, the predominant ISG15 conjugation and deconjugation enzymes, UbE1L, UbcH8/UbcM8, 
HERC5/HERC6, and UBP43/USP18 are all induced by type I IFN stimulation.  Secondly, the 
ubiquitin conjugation system is constituted by many E2 and E3 proteins
1
.  It is the binding 
specificity of E2 to E3 and E3 to target proteins that allows for ubiquitin to affect such a vast 
number of biological processes with such specificity.  In contrast, it seems that formation of the 
overwhelming majority of ISG15 conjugates occurs through one E2 enzyme and one E3 enzyme.  
Finally, there is no evidence that ISG15 conjugates to itself and forms ISG15 chains in the 
manner of poly-ubiquitin modification.  While not fully understood, these differences between 
the ISG15 and ubiquitin pathways most likely reflect the specific function of ISG15 conjugation. 
ISG15 has been implicated in regulating numerous biochemical pathways, and the 
generation and study of ISG15 deficient mice have revealed that it plays an important role during 
viral infection.  Data collected to date has demonstrated that ISG15 can protect against a wide 
gamut of viruses, and the mechanisms by which it mediates this protection are varied.  Here we 
will review the progress that has been made in the identification of viruses that are regulated by 
ISG15 and the mechanisms by which ISG15 mediates this protection.   
 
 7 
 
 
Antiviral Activity of ISG15 
The antiviral activity of ISG15 was first observed in a screen designed to identify 
antiviral interferon stimulated genes (ISG) important during Sindbis virus infection
37
.  
Recombinant Sindbis viruses were engineered to express ISGs, and these ISGs were then 
evaluated for their ability to protect IFNAR-/- mice from lethality after infection.  Mice infected 
with a Sindbis virus expressing ISG15 but not a control virus were protected from virus induced 
lethality.  This discovery was followed by numerous reports of ISG15 antiviral activity observed 
in tissue culture under conditions of ISG15 overexpression and siRNA knockdown.  Influenza 
virus, vaccinia virus, vesicular stomatitis virus (VSV), Sendai virus (SeV), Japanese encephalitis 
virus (JEV), Newcastle disease virus (NDV), avian sarcoma leucosis virus (ASLV), human 
papilloma virus (HPV),  human immunodeficiency virus 1 (HIV-1), Ebola virus-like particles 
(VLPs), dengue virus, and West Nile virus (WNV) have all been reported to be modestly 
inhibited by ISG15 in vitro.  For several viruses contradictory results have been reported with 
regards to whether ISG15 antagonizes virus replication.  These discrepancies are likely a result 
of different experimental conditions.  In the case of influenza A virus it has been reported that 
inhibition of replication by ISG15 is species and/or cell type specific
38
.  
Importantly, the generation of ISG15 deficient mice has allowed for the verification of 
the antiviral activity of ISG15 in vivo 
39
.  As predicted, ISG15-/- mice infected with Sindbis virus 
were found to be more susceptible to lethality than WT mice 
40
.  The increased lethality observed 
in the ISG15-/- mice could be rescued when the mice were infected with a recombinant virus 
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expressing wild type (WT) ISG15, but not when infected with a recombinant virus expressing an 
ISG15(LRLRAA) mutant incapable of forming conjugates
40
.  This suggested that in this viral 
model the antiviral activity of ISG15 was dependent upon its ability to ISGylate proteins.  A 
subsequent study confirmed the conjugation dependence of this protection by showing that 
UbE1L-/- mice are also more susceptible than WT mice to Sindbis virus infection
41
.     
Increased mortality was also observed in ISG15-/- mice after infection with influenza A 
and influenza B viruses
40; 42
.  During influenza B virus infection, viral loads in WT mice 
remained very low over the course of infection and the mice experienced minimal weight loss or 
other clinical signs of illness.  In contrast, ISG15-/- mice experienced dramatic weight loss and 
viral loads reached levels up to 1000 fold higher than in WT mice at late time points.  These 
observations were found to be true for both the mouse-adapted influenza B/Lee/40 strain, and a 
non-mouse-adapted influenza B/Yamagata/88 strain, indicating that ISG15 may contribute to the 
species tropism barrier for influenza B virus infection.  UbE1L-/- mice infected with influenza B 
virus similarly exhibited increased lethality and increased viral burden compared to WT mice, 
suggesting that ISG15 mediated protection from influenza B virus is also dependent on the 
ability of ISG15 to form conjugates
42
.  Bone marrow chimera studies suggest that the expression 
of ISG15 in a radioresistant cell line is responsible for mediating this protection, however, it 
remains unclear as to how ISG15 conjugation is affecting influenza B virus replication
42
. 
These initial studies established the precedent of ISG15 antiviral activity in vivo.  
Subsequent studies have identified additional viruses that ISG15 mediates protection against in 
vivo.  Increased susceptibility has been seen with Chikungunya virus (CHIKV), herpes simplex 
virus-1 (HSV-1), gamma herpes virus 68 (HV68), and vaccinia virus infections.  However, 
despite this diverse array of viruses that appear to be affected by ISG15, ISG15-/- mice have not 
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displayed increased susceptibility to all viruses tested.  No phenotype was observed following 
infection of ISG15-/- mice with lymphocytic choriomeningitis virus (LCMV) or VSV
39
.  Our lab 
also has not observed increased susceptibility in ISG15-/- mice after WNV infection (D. 
Lenschow, unpublished observations).   
After the discovery of ISG15, much attention was invested in studying ISG15 
conjugation.  The initial discoveries of conjugation mediated protection against Sindbis virus and 
influenza B virus seemed to corroborate the importance of ISGylation.  Recently, however, it has 
been reported that while ISG15-/- mice are more susceptible to CHIKV infection, UbE1L-/- mice 
display similar susceptibility to CHIKV as WT mice, suggesting a conjugation independent role 
for ISG15 during virus infection
43
.  This phenomenon has also been observed with Ross River 
virus infection (D. Lenschow, unpublished observations).  In vitro and in vivo studies have 
shown that the antiviral activity of ISG15 targets viruses from diverse families ranging from 
retroviruses (HIV-1, ASLV), to large DNA viruses (vaccinia virus, HSV-1), to both positive and 
negative sense RNA viruses (Sindbis virus, Influenza A virus respectively)
40; 44; 45; 46
.  The 
mechanisms through which ISG15 mediates protection are likely to be just as diverse.  Below we 
will cover what is currently known about the mechanisms through which ISG15 exerts its 
protective effects. 
 
Mechanisms of ISG15 Activity 
Inhibition of virus release: 
Several studies have found that ISG15 can impact the viral life cycle at the stage of virus 
release.  This has been seen with the retroviruses HIV-1 and ASLV, and also with Ebola virus.  
 10 
Despite impacting the release of all of these viruses, detailed studies have identified different 
mechanisms through which ISG15 is acting.  The first evidence of ISG15 inhibiting virus release 
was observed when characterizing the effect of ISG15 on HIV-1 replication.  The replication of 
HIV-1 in 293T cells transfected with HIV-1 proviral DNA was found to be inhibited when 
cotransfected with a plasmid expressing ISG15
44
.  While ISG15 inhibited HIV-1 release into the 
supernatant, it did not affect HIV-1 protein production.  Expression of ISG15 was shown to 
inhibit the ubiquitination the HIV-1 Gag protein and the interaction between Gag and Tsg101.  
Both of these events are important for mediating HIV-1 budding and release
47
.  Interestingly, 
while cotransfection of UbE1L enhanced HIV-1 inhibition, the ectopic expression of ISG15 
alone could inhibit the Gag-Tsg101 interaction, raising the possibility that the unconjugated form 
of ISG15 may be partly mediating this inhibition.  A subsequent study has shown that HERC5 
mediated ISG15 conjugation can inhibit HIV-1 budding from the plasma membrane
48
.  Unlike 
the initial HIV-1 study, this group found that the HIV-1 Gag protein is ISGylated by HERC5.  It 
was also shown that overexpression of ISG15 without HERC5 resulted in an accumulation of 
Gag in cytoplasmic clusters, whereas co-expression of ISG15 with HERC5 resulted in an 
accumulation of Gag at the plasma membrane.  These results suggest that unconjugated ISG15 
and ISGylation may act to block HIV-1 budding by two distinct mechanisms. 
ISG15 was also shown to inhibit Ebola VLP budding by a similar mechanism.  
Expression of the Ebola matrix protein, VP40, alone is sufficient to produce budding and release 
of VP40 VLPs
49
.  This release is regulated by the ubiquitin E3 ligase Nedd4 through a 
mechanism dependent on its ligase activity
50
.  Two studies demonstrated that the coexpression of 
ISG15 with VP40 can inhibit VP40 VLP release by inhibiting Nedd4 ligase activity, and thus 
inhibiting ubiquitination of VP40
51; 52
.  Like the HIV-1 studies, overexpression of ISG15 alone 
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was able to disrupt Ebola VLP release, suggesting that unconjugated ISG15 may be capable of 
inhibiting Nedd4 ligase activity
52
.   Malakhova et al. was able to show that purified ISG15 
protein was able to disrupt the ability of Nedd4 to bind to ubiquitin E2 conjugating enzymes, 
thus preventing ubiquitin from being transferred to the catalytic cysteine residue of Nedd4
51
.  
This study further showed that ISG15 could inhibit other Nedd4-like E3 ligases from augmenting 
VP40 VLP release.  The ISG15 disruption of ubiquitin-mediated regulation during both Ebola 
virus and HIV-1 release raises an intriguing model for general ISG15 regulation through 
ubiquitin antagonism.  It is possible that unconjugated ISG15 could compete with ubiquitin by 
binding to ubiquitin interacting domains in proteins or by forming thioester bonds with ubiquitin 
E2 or E3 enzymes.  Additionally, ISG15 conjugation to Ubc13 on a lysine residue that is 
normally ubiquitinated has been reported to inhibit the E2 conjugating activity of Ubc13
53; 54
.  
Thus competing for target lysine residues is yet another mechanism by which ISG15 can 
antagonize ubiquitin.   
Studies of the retrovirus ASLV revealed yet another mechanism by which ISG15 can 
inhibit virus budding
45; 55
.  ASLV budding and release is dependent upon Gag binding to 
Nedd4
47
.  Despite the observed effects of ISG15 on Nedd4 in the Ebola studies, co-transfection 
of ISG15 with the ASLV Gag protein inhibited ASLV VLP release without disrupting the 
interaction between Gag and Nedd4.  The disruption of Gag-Tsg101 interaction in the HIV-1 
study suggested that ISG15 is disrupting an early stage in the endosomal sorting complexes 
required for transport (ESCRT) pathway.  Chimeric HIV-1 or ASLV Gag proteins fused to 
downstream ESCRT proteins can bypass early stages of the ESCRT pathway to facilitate VLP 
release
47
.  However, in a study by Pincetic et al. it was found that ASLV Gag-ESCRT chimeras 
were still sensitive to ISG15 mediated inhibition
45
.  ISG15 was found to prevent VLP release by 
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inhibiting the recruitment of the AAA-ATPase Vps4 to the ESCRT pathway.  This inhibition of 
Vps4 recruitment was dependent on charged multivesicular body protein (CHMP) 5 and 
correlated with ISGylation of CHMP5.  However, other CHMP proteins were also found to be 
ISGylated in this study, and the mechanism by which ISG15 mediates this modulation of the 
ESCRT pathway was not conclusively shown.   
It is not clear whether the ISG15 manipulation of the ESCRT pathway represents a 
general strategy for the inhibition virus propagation.  Notably, both LCMV and HSV-1 have 
been shown to utilize the ESCRT pathway for virus budding, yet ISG15 has not been found to 
affect LCMV pathogenesis in vivo or inhibit HSV-1 replication in vitro
39; 40; 56; 57; 58
.  It is 
possible that these viruses are capable of antagonizing ISG15 and its effects on the ESCRT 
pathway.  More studies will be needed to more precisely define the mechanisms by which ISG15 
regulates viral budding.  It will also be interesting to determine if ISG15 alteration of the ESCRT 
pathway represents specific strategy for targeting viruses, or if this might be reflective of a 
broader role that ISG15 plays in vesicular trafficking after IFN stimulation.   
 
ISGylation of Viral proteins 
The recombinant Sindbis virus studies not only demonstrated that ISG15 could act as an 
antiviral molecule, but also showed that it could do so when expressed only from within the virus 
genome, exerting its activity from within a virally infected cell
37; 40
.  Similarly, knock-down of 
ISG15 in human cells was shown to increase influenza A virus replication, further suggesting 
that ISG15 can directly antagonize virus replication and sparking subsequent studies exploring 
the possibility of ISG15 acting by directly conjugating to viral proteins
38
.  Indeed, there now is 
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evidence that during some infections viral proteins are targeted for ISGylation and this 
contributes to the type I IFN mediated inhibition of virus replication.   
The first viral protein shown to be modified by ISG15 was the NS1 protein of influenza 
A virus.  Two studies have been published showing that influenza A virus NS1 protein can be 
ISGylated by HERC5, and different functional consequences have been attributed to this 
modification
59; 60
.  Both studies found that NS1 is ISGylated on more than one lysine residue.  
Zhao et al. found that the lysine residue at position K41 was the dominant site for ISGylation
59
.  
Modification at this site was shown to have no impact on the ability of NS1 to bind to double 
stranded RNA but did inhibit its ability to interact with importin alpha, an interaction involved in 
the nuclear translocation of NS1.  A recombinant influenza A virus containing the K41A 
mutation in its NS1 protein to reduce ISGylation of NS1 was less susceptible to inhibition of 
replication by IFN as compared to a WT virus.  Tang et al. found that seven lysines in NS1 had 
to be mutated to generate a non-ISGylated NS1
60
.  This study found that ISGylated NS1 could 
not interact with the N-terminus of PKR, the RNA binding domain of NS1, U6snRNA, or 
dsRNA.  On a functional level, ISGylation of NS1 inhibited the ability of NS1 to antagonize the 
induction of ISGs by SeV infection, suggesting that ISGylation of NS1 would render influenza A 
virus more susceptible to the antiviral response.  Differences in the findings of these two studies 
could be due to the different strains of influenza A virus that were used in each study.  However, 
both studies further support the hypothesis that by modifying viral proteins ISG15 can directly 
antagonize virus replication.   
The HPV capsid protein has also been shown to be ISGylated by HERC5
25
.  Using a 
HPV pseudovirus packaging system, Durfee et al. demonstrated that the expression of the ISG15 
conjugation system led to the ISGylation of the HPV capsid protein, which then incorporated 
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into released virus.  ISGylation of HPV capsid protein correlated with a decrease both in the 
amount of virus released and in the subsequent infectivity of the virus produced in the presence 
of ISG15.  This observation led to a model in which ISGylated capsid protein is incorporated 
into virions but results in an alteration of the geometry of the viral capsid.  It is hypothesized that 
this change in the capsid structure then inhibits the infectivity of the released virus.  As 
mentioned previously, Woods et al. also found that HIV-1 Gag protein can also be ISGylated by 
HERC5 
48
.  It is important to note that direct causality of virus replication inhibition through 
viral protein ISGylation, as opposed to ISGylation of host proteins, was not verified with non-
ISGylatable HPV capsid or HIV-1 Gag mutants.  Nonetheless, these observations help to further 
an attractive model for ISG15 function that could help to explain how ISGylation of a small 
fraction of the total pool of a protein could lead to a large downstream effect on virus fitness.  
Homooligomerization of viral proteins is a universal necessity in viral genomes to facilitate 
virion formation and genome packaging.  Future studies will be needed to determine if this 
model can be applied to other viral proteins such as matrix proteins or ribonucleoproteins.   
 
Modification of host proteins: 
Since ISGylation has been shown to target newly translated proteins, ISGs would be 
predicted to be a population of proteins rife with targets for ISG15 conjugation following IFN 
stimulation.  In one of the first high throughput studies identifying ISGylated proteins, both Jak1 
and STAT1 were shown to be ISGylated in human thymus tissue
61
.  In subsequent proteomic 
studies, many ISGs have been identified as ISG15 targets
33; 34
.  Among these, three antiviral 
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effectors, interferon regulatory factor 3 (IRF3), retinoic acid inducible gene 1 (RIG-I), and 
protein kinase R (PKR) have been analyzed in significant detail.     
ISGylation of IRF3 has been reported to stabilize activated IRF3, thus positively 
regulating the type I IFN response
62; 63
.  Shi et al. showed that after SeV infection, HERC5 can 
bind to and ISGylate IRF3 on multiple lysine residues.  ISGylation of IRF3 inhibits the 
interaction of IRF3 with PIN1 thus inhibiting the ubiquitination and degradation of IRF3, 
resulting in a more robust IFN response
63
.  This study went on to show that siRNA knock down 
of HERC5 or ISG15 resulted in increased replication of VSV, SeV, and NDV.  However, it is 
unclear from these studies whether inhibition of virus replication was dependent on ISGylation 
of IRF3 or if ISGylation of other target proteins mediated these antiviral effects.   
RIG-I was found to be ISGylated after transfection of COS-7 cells with ISG15, UbE1L 
and UbcH8 expression plasmids
64
.  Overexpression of the ISG15 conjugation system also 
resulted in decreased levels of non-ISGylated RIG-I, though this decrease was not dependent on 
proteasome activity.  This reduction of RIG-I levels was not seen in UbE1L-/- MEFS further 
implicating the importance of ISG15 conjugation to mediate this phenomenon.  The reduction of 
RIG-I protein levels correlated with a reduction in the intensity of the IFN response triggered by 
NDV
64
.  In this study the residues modified by ISG15 were not identified and mutated, so it 
could not be ruled out that the decrease in RIG-I expression was an indirect result of the 
ISGylation of another protein.  Whether directly a result of RIG-I ISGylation or not, this study 
suggests that ISG15 might not always engender a more intense IFN response, but rather it may 
act to dampen the IFN response down to an appropriate level in certain scenarios. 
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PKR was also identified in proteomic analysis as being a target of ISGylation
33; 34
.  
Okumura et al. recently verified that PKR is ISGylated after IFN or LPS stimulation
65
.  
Mutational analysis revealed that PKR is ISGylated at K69 and K159.  In lung fibroblasts PKR 
was found to be activated even in the absence of viral RNA, however this activation was 
dependent on ISG15.  A non-ISGylatable K69R, K159R PKR mutant did not exhibit constitutive 
activation demonstrating that this RNA independent activation of PKR was due to ISGylation of 
PKR.  This increased activation of PKR was also observed when ISG15 was fused to the N-
terminus of PKR resulting in increased phosphorylation of eIF2 and decreased protein 
synthesis.  These findings suggest ISG15 may have a broader impact on protein translation prior 
to viral infection.   
While the ISG15 mediated regulation of antiviral effectors has received much attention, it 
is also important to understand how ISGylation of other “non-antiviral effector” proteins might 
affect virus replication and pathogenesis.  For example, as previously discussed, ISGylation of 
CHMP5 has been correlated with the ISG15-dependent inhibition of HIV-1 budding
55
.  ISG15 
has also been implicated in the regulation of IFN induced apoptosis through modification of 
filamin B
66
.  In addition to cross-linking actin filaments, filamin B also serves as a scaffold 
protein for the Jun N-terminal kinase (JNK) signaling pathway.  Jeon et al. has shown that 
ISGylation of filamin B disrupts its ability to bind to RAC-1, MEKK1, and MEKK4, thereby 
inhibiting the signaling cascade leading to JNK mediated apoptosis
66
.  In this study coexpression 
of UbcH8 and filamin B resulted in co-localization of the two proteins in actin rich membrane 
ruffles.  Thus while only a small fraction of total filamin B is ISGylated, the fraction of 
ISGylated filamin B within the local microenvironment of a membrane ruffle might be quite 
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high.  This might explain how ISGylation of a seemingly small fraction of filamin B can have a 
large impact on JNK signaling.   
It is important to note that despite the number of studies evaluating the regulation of ISGs 
by ISG15, no studies in ISG15-/- mice or ISG15-/- cells have demonstrated ISG15 conjugation 
as having a role in the regulation of the type I IFN response.  Analysis of cells from ISG15-/- and 
UbE1L-/- mice did not reveal any misregulation of STAT1 activation or ISG induction after 
stimulation with IFN beta, LPS, or combinations of both stimuli
14; 39
.  PolyI:C injections of mice 
had no effect on cell proliferation, and UbE1L-/- cells were found to undergo similar levels of 
apoptosis after IFN stimulation.  There could be several explanations for these discrepancies 
including 1) the differences in utilization of overexpression, knockdown, and knockout systems, 
2) differences between the function of ISGylation in humans and mice, or 3) differences in 
experimental conditions and types of stimulations.  Additional studies will be required to better 
understand these discrepancies. 
 
Unconjugated ISG15 
In addition to existing in its conjugated form, ISG15 is present in an unconjugated form 
both intracellularly and released into the extracellular space.  Recent evidence in both murine 
and human models has indicated that unconjugated ISG15 may also play an important role in the 
host response to infections. 
A recent study by Werneke et al. was the first in vivo study to suggest that unconjugated 
ISG15 has a biologically relevant role during infection
43
.  In this study, ISG15-/- neonatal mice 
were found to be highly susceptible to infection with the re-emerging viral pathogen, CHIKV.  
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However UbE1L-/- mice did not display increase lethality, indicating that the expression of 
unconjugated ISG15 was sufficient to protect these mice from CHIKV induced lethality.  The 
protective mechanism of ISG15 in this model was distinct from previous models that have been 
studied, in that ISG15 did not appear to function as an antiviral molecule.  Viral loads in all 
organs examined were the same in WT, UbE1L-/- and ISG15-/- mice.  Instead the ISG15-/- mice 
had significantly higher levels of multiple cytokines in their serum, and death of the animals 
occurred in a manner consistent with a cytokine storm.  Together these data suggested that 
unconjugated ISG15 protected these neonatal mice from CHIKV induced lethality through its 
ability to regulate the production of proinflammatory cytokines and chemokines.  The 
mechanism through which ISG15 regulates these responses and the cell types responsible for the 
increased cytokine production in this model are not known.  A recombinant CHIKV engineered 
to express ISG15 was no less virulent than the WT virus in ISG15-/- mice.  This suggests that 
unconjugated ISG15 may need to be expressed by non-infected cells, or expressed before virus 
infection in order to mediate protection.  It is also not certain whether intracellular unconjugated 
ISG15 or extracellular unconjugated ISG15 is responsible for the regulation of cytokines in this 
model.  Future studies will be needed to address these important questions. 
ISG15 has long been implicated as having a role as a cytokine-like molecule. Though 
ISG15 has no canonical signal peptide for release, T-cells, B-cells, monocytes, and epithelial 
cells have all been shown to release ISG15 after IFN stimulation in vitro
67
.  In studying the 
potential role for this released ISG15, it was found that treatment of peripheral blood 
lymphocytes with recombinant ISG15 resulted in specific proliferation of natural killer (NK) 
cells
68
.  This expansion of NK cells was found to be due to the induction of IFN gamma by T-
cells.  Recently, a study by Bogunovic et al. confirmed a role for unconjugated ISG15 in the 
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stimulation of IFN gamma production and correlated this function with increased disease 
susceptibility in humans
69
.  In this study ISG15 deficiency was identified as a potential 
predisposition for Mendelian susceptibility to mycobacterial disease.  These authors found that 
recombinant ISG15 induced IFN gamma production by both NK cells and other lymphocytes.  
They went on to show that the levels of IFN gamma produced after stimulation with recombinant 
ISG15 was greatly enhanced by co-stimulation of cells with ISG15 and IL-12.  Whole blood 
cells from ISG15 deficient individuals produced decreased levels of IFN gamma compared to 
cells from ISG15 sufficient individuals after stimulation with either mycobacteria alone or in 
combination with IL-12.  Treatment of ISG15 deficient cells with recombinant ISG15 in addition 
to mycobacteria and IL-12 enhanced their ability to produce IFN gamma to levels near ISG15 
sufficient cells.  This data indicates that released ISG15 may play an important role in IFN 
gamma production during mycobacterial infection. 
Together these studies suggest that ISG15 contributes to the host response to infection 
not only through its modification of target proteins, but also through the actions of unconjugated 
ISG15, perhaps functioning as a cytokine.  Many questions still remain, including the identity of 
a receptor that can mediate these biological properties.  Given the therapeutic potential for 
administration or inhibition of cytokines during viral infection, it is of great interest to further 
define the role of ISG15 in cytokine regulation.   
 
Viral countermeasures: 
Viral antagonism of antiviral effectors is a phenomenon so frequent and inevitable that 
the study of mutant viruses is routinely a means by which novel host biology is elucidated.  
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Discoveries of viral antagonism of ISG15 have further highlighted the importance of ISG15 as a 
part of the host antiviral response.  Before the antiviral activity of ISG15 had been demonstrated, 
a role for ISG15 during influenza B virus infection was eluded to by the discovery of the 
interaction between ISG15 and the influenza B virus NS1 protein (B/NS1)
11
.  Influenza B/NS1, 
but not influenza A/NS1, was found to bind ISG15 and inhibit it from interacting with UbE1L, 
thereby preventing the formation of ISG15 conjugates.  A detailed review covering the 
interaction between B/NS1 and ISG15 has recently been published
70
.  Since this discovery of 
B/NS1 interacting with ISG15, several other viruses have also been identified that encode 
proteins that can interact with and potentially antagonize ISG15. 
The vaccinia E3L protein initially masked the sensitivity of vaccinia virus to ISG15
46
.  A 
WT vaccinia strain replicated to similar levels in ISG15-/- and WT mouse embryonic fibroblasts 
(MEF) after 48 hours of infection, and ISG15-/- mice did not exhibit increased lethality 
compared to WT mice.  However, after infection with WT vaccinia virus, it was noted that 
ISG15 was induced but did not form conjugates.  Infection of cells with a E3L mutant vaccinia 
virus did result in ISG15 conjugate formation.  The E3L protein was shown to bind to ISG15, 
suggesting that the E3L protein directly antagonizes ISG15 conjugation, though the exact 
mechanism by which this occurs is not known.  ISG15-/- mice exhibited increased lethality 
compared to WT mice when infected with this E3L mutant vaccinia virus, and the mutant virus 
exhibited a ~25 fold increase in virus replication in ISG15-/- MEFs compared to WT MEFs.  
Therefore, similar to influenza B virus, vaccinia virus appears to have evolved a mechanism to 
disrupt ISG15 conjugation and its antiviral activity.   
Multiple viruses have evolved deubiquitinating enzymes capable of antagonizing host 
cell biology.  Several of these viral proteins are capable of deconjugating ISG15 from ISGylated 
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target proteins.  Crimean-Congo hemorrhagic fever virus (CCHFV) and equine arteritis virus 
encode L proteins containing ovarian tumor (OTU) domains.  In host proteins OTU domains can 
contain ubiquitin deconjugation activity
32
.  When transfected into cells, these viral L proteins 
were able to reduce the total pool of both ubiquitin and ISG15 conjugates
71
.  Expression of the 
CCHFV L protein OTU domain by recombinant Sindbis virus in parallel with expression of 
ISG15 abolished the protection provided by ISG15 during infection of IFNAR-/- mice
71
.  
Similarly, SARS-Coronavirus encodes a papain-like protease that has been shown to cleave K48 
linked ubiquitin chains as well as ISG15 fusion proteins
72; 73; 74
.  While these examples highlight 
another potential mechanism of circumventing ISG15, direct evidence for ISG15 antagonism by 
these proteins remains to be demonstrated during viral infection. 
The convergent evolution of viral proteins antagonizing the ISG15 conjugation system 
demonstrates the broad antiviral activity of ISG15.  It will be interesting to investigate whether 
the lack of a role for ISG15 during infections with certain viruses, such as VSV and LCMV, 
might also be due to viral antagonism of ISG15 that has yet to be discovered. 
 
THESIS GOALS 
ISG15 was the first ubiquitin-like modifier to be identified, yet over 25 years after its discovery 
remarkably little is known about the molecular functions of ISG15 and ISG15 conjugation.  
Studies of ISG15 deficient mice have clearly established that ISG15 can mediate protection from 
virus induced lethality, however the molecular mechanisms mediating this protection are still not 
well understood. 
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Hundreds of host proteins have been identified as targets of ISGylation by mass 
spectrometry.  Historically, the predominant strategy for studying ISG15 function has been a 
reverse genetics style of approach by verifying ISGylation of a target of interest, identifying the 
modified lysine residue in the target protein, and generating a non-ISGylatable mutant version of 
the protein to study the effects of ISGylation.  Studying the effects of ISG15 conjugation through 
this approach has proved to be difficult for several reasons.  Firstly, a number of proteins have 
been shown to be capable of being ISGylated on multiple lysine residues.  It is unclear whether 
the targets are normally modified on multiple residues, or if ISG15 simply targets new lysine 
residues after one residue is mutated.  In the case of the influenza A virus NS1 protein, one study 
found that seven lysine residues had to be mutated before a non-ISGylatable mutant was 
obtained 
60
.  Mutating large numbers of lysines risks affecting the function of the target and thus 
confounding subsequent studies of the impact of ISG15 on the target protein.  Secondly, while 
some studies have identified consequences of ISGylation, typically only ~5% of the total pool of 
a target protein is ISGylated.  Most reported effects of ISGylation have been attributed to the 
disruption of interactions between the ISGylated protein and its normal binding partners.  
However, most studies fail to demonstrate how ISGylation of such a small fraction of the target 
protein might lead to a biologically relevant phenotype.  Thirdly, one study has suggested that 
ISGylation through the E3 ligase HERC5 targets newly translated proteins with no apparent 
sequence specificity driving the conjugation of ISG15 to target proteins 
25
.  This finding raises 
the question of whether exogenous overexpression of the ISG15 conjugation system or target 
proteins will faithfully recapitulate the effects of ISGylation on the endogenous target protein 
after interferon stimulation.  
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 While ISGylation of viral proteins has been reported, and in at least some systems may 
contribute to the antiviral activity of ISG15, virus replication has not been altered in several 
models where ISG15 is known to play a role during virus infection in vivo.  For example, ISG15-
/- mice display increased lethality following Sindbis virus infection, however, no defect in virus 
replication was observed when WT and ISG15-/- MEFs were infected with Sindbis virus
40
.  
Similarly, ISG15-/- mice are more susceptible to HSV-1 infection, however no difference in 
HSV-1 replication has been observed in ISG15-/- MEFs or in fibroblasts from human patients 
deficient for ISG15
40; 69
.  Discrepancies between in vivo protection and cell culture phenotypes 
might be a result of the particular cell types chosen for study.  However, it is also possible that 
ISG15 mediated protection from lethality might not be a result of direct antagonism of virus 
replication, as has been demonstrated for CHIKV infection
43
.  
To date, the most profound and consistent phenotypes demonstrated for ISG15 has been 
the increased susceptibility of ISG15-/- mice to viral infections in vivo.  Therefore, we have 
chosen to take a forward genetics style of approach to investigating the function of ISG15 by 
dissecting the mechanisms behind the susceptibility of ISG15-/- mice to viral infection.   
Arguably the most robust in vivo phenotype in ISG15-/- and UbE1L-/- mice is their 
susceptibility to influenza B virus infection.  While ISG15 mediated inhibition of virus 
replication has been demonstrated in tissue culture for a number of viruses, the reported effects 
have been modest, ~5-10 fold.  Given the dramatic inhibition of influenza B virus replication by 
ISG15 in vivo, I set out to use influenza B virus infection as a model for studying the effects of 
ISG15 on the virus life cycle.  I aimed to answer three main questions:  1.) Can ISG15 directly 
inhibit influenza B virus replication in primary trachea epithelial cell (mTEC) cultures in vitro?, 
2.) Does increasing ISG15 conjugation provide increased protection against influenza B virus 
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infection?, and 3.) Are influenza B virus proteins targets of ISGylation, and if so what effect 
does ISGylation have on the virus life cycle? 
The hypothesis that ISG15 protects mice from viral infection by inhibiting virus 
replication largely stems from two observations.  First, the type I interferon system has a well 
established role of antagonizing virus replication, and ISG15 is one of the most rapidly and 
strongly induced genes after type I interferon stimulation.  And second, influenza B virus 
replicates to levels ~100 fold greater in ISG15-/- mice compared to WT mice.  However, the 
recent evaluation of CHKV pathogenesis in ISG15-/- mice demonstrates that ISG15 can confer 
resistance to viral infection without affecting virus burden, demonstrating that further evaluation 
of the role of ISG15 during other in vivo infection models is warranted.  Therefore I chose to 
characterize the role of ISG15 and ISG15 conjugation during infection with two other respiratory 
viruses, influenza A virus and Sendai virus. 
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Figure 1.1 A comparison between the ubiquitin and ISG15 conjugation pathways. 
Both ubiquitin and ISG15 are conjugated to target proteins by utilizing enzymatic cascades 
composed of E1, E2, and E3 enzymes.  A) In the case of ubiquitin, it achieves specificity in 
target protein modification through the use of multiple E2 and E3 enzymes, which can 
orchestrate a broad range of specific ubiquitin modifications.  Ubiquitin can also conjugate to 
itself on multiple lysine residues to form polyubiquitin chains on target proteins which result in 
different downstream functional consequences for the targeted protein.   B) The ISG15 
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conjugation cascade is an IFN induced cascade in which the vast majority of ISG15 conjugation 
utilizes UbE1L, UbcH8, and HERC5.  Interaction between HERC5 and polysomes leads to the 
preferential ISGylation of newly translated proteins.  Unlike ubiquitin, there is no evidence that 
ISG15 forms poly-ISG15 chains or targets proteins for degradation.   
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INTRODUCTION 
The history of the ISG15 field is intimately tied to influenza B virus (IBV).  ISG15 was 
first identified as an interferon stimulated gene in 1984 in a study evaluating proteins induced 
after type I interferon stimulation 
1
.  Soon afterwards ISG15 was found to be induced upon 
infection of cells with encephalomyocarditis virus 
2
.  While these observations associated the 
expression of ISG15 with the type I interferon response and virus infection, the first indication 
that ISG15 might have a role in modulating the virus life cycle came from a study showing that 
IBV inhibits ISG15 conjugation 
3
.  This study used a yeast two-hybrid assay to screen a cDNA 
library for genes encoding proteins that interacted with the influenza B virus NS1 protein 
(B/NS1), but not the influenza A virus NS1 protein.   B/NS1 was found to bind to ISG15 and 
inhibit it from forming the ISG15-activating thioester bond with its E1 activating enzyme, 
UbE1L, thus inhibiting ISG15 conjugation.  Since then it has been shown that this effect is 
species specific, as B/NS1 can bind to human ISG15 but not murine ISG15, and that 
coexpression of B/NS1 with ISG15 results in a relocalization of ISG15 from the cytoplasm to the 
nucleus 
4
. 
The inhibition of ISGylation by B/NS1 suggested an important role for ISG15 during 
IBV infection, and the generation of ISG15-/- mice ultimately validated this hypothesis.  ISG15-
/- mice are dramatically more susceptibility than WT mice to IBV infection, as ~80% of ISG15-
/- mice succumb to infection when given a dose that causes ~5% weight loss and virtually no 
lethality in WT mice
5
.  Evaluation of lung viral loads over the course of infection found that the 
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increased disease in ISG15-/- mice is associated with increased viral loads that reach ~100-1000 
fold greater levels in ISG15-/- mice than in WT mice.   
In addition to the induction of intracellular ISG15 and ISG15 conjugates, non-conjugated 
(“free”) ISG15 was also observed in the serum of mice after IBV infection5.  While ISG15 exists 
in these three different forms, the specific inhibition of ISG15 conjugation by B/NS1 suggested 
that ISGylation, and not expression of free ISG15 alone, mediated the protective effects against 
IBV.  Supporting this hypothesis, UbE1L-/- mice, which express ISG15 but cannot form ISG15 
conjugates, were found to also exhibit increased lethality and increased virus burden compared to 
WT mice after influenza B virus infection 
6
.  This sensitivity of IBV to ISG15 conjugation, and 
the general susceptibility of ISG15-/- mice to viral infection, suggests that exogenous 
manipulation of the ISG15 conjugation pathway to increase ISGylation might serve as a novel 
antiviral strategy. 
The level of ISG15 conjugation in a cell depends on three factors: 1.) the expression level 
of ISG15, 2.) the enzymatic rate of forming ISG15 conjugates, and 3.) the rate at which ISG15 is 
deconjugated from targeted proteins.  Previous studies have demonstrated that UBP43(USP18) 
can act as an ISG15 specific deconjugating enzyme 
7
.  Therefore one approach to increase ISG15 
conjugation would be to inhibit the activity of UBP43.  In fact, this strategy of increasing 
ISGylation to study the effects of ISG15 modification was the logic behind the generation and 
characterization of UBP43-/- mice.  Interestingly, while UBP43-/- mice could be generated on a 
mixed genetic background, it was found that backcrossing UBP43-/- mice to an inbred C57BL/6 
background resulted in embryonic lethality (data not shown)
8
.  Though viable, these UBP43-/- 
mice developed hydrocephalous and did not survive past 20 weeks of age.  While UBP43-/- mice 
displayed increased protection against both viral and bacterial infections, they also exhibited 
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hypersensitivity to poly(I:C) as they display increased lethality compared to WT mice after 
intraperitoneal injection of poly(I:C)  
9; 10; 11
.  Microarray analysis of UBP43-/- cells showed that 
these cells had a global increase in the expression of IFN stimulated genes compared to WT cells 
12
.  Taken together, these data were originally interpreted as demonstrating that ISG15 
conjugation augments the IFN response.   
However, a careful re-evaluation of UBP43-/- mice revealed that UBP43 has a second 
function that confounds the interpretation of the initial UBP43-/- mouse characterization.  When 
UBP43-/- mice were bred onto the ISG15-/- background, it was discovered that UBP43-/-
xISG15-/- mice retained a hypersensitive interferon response compared to WT mice, and still 
developed hydrocephalus 
11
.  Further re-evaluation of UBP43 function found that UBP43 can 
compete with JAK1 for binding to the type I interferon receptor 2 (IFNAR2), and thus inhibit 
IFN signaling 
13
.  This inhibition of IFN signaling was shown to occur independent of the 
deconjugating activity of UBP43.  Consequently, the upregulation of ISG expression, and even 
the increased level of ISG15 conjugates, observed in the UBP43-/- mice cannot be directly 
attributed to the absence of UBP43 deconjugation activity.   Therefore it remains to be 
determined whether enzymatic inhibition of UBP43 would increase protection against virus 
infection.   
To date, increased susceptibility to IBV is one of the strongest phenotypes that has been 
observed in ISG15-/- mice.  While the increased viral loads observed in ISG15-/- mice suggests 
that ISG15 acts by inhibiting virus replication, no difference in IBV replication was observed in 
WT and ISG15-/- murine embryonic fibroblasts (MEF) 
5
.  This discrepancy between the effects 
of ISG15 on IBV replication in vivo and in vitro could be explained if the in vivo inhibition of 
virus replication is not cell intrinsic but, rather, is mediated by ISG15 regulation of the innate 
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immune response.  However, previous evaluation of IBV replication in WT and ISG15-/- bone 
marrow chimeric mice suggested that ISG15 expression within the radio-resistant compartment 
mediated the important function of ISG15 during infection.  Only irradiated/reconstituted WT 
mice were able to control virus replication and they could do so irrespective of the genotype of 
the bone marrow with which they were reconstituted 
6
.  While this does not rule out ISG15 
regulation of the immune response as the key mediator for inhibition of IBV replication, we 
hypothesized that ISG15 was directly antagonizing virus replication in infected cells.  Influenza 
virus replicates both in the bronchiolar epithelium and in alveolar epithelial cells in vivo.  While 
our lab previously reported no difference in IBV replication in ISG15-/- MEFs, these cells are 
not an ideal cell line for studying influenza virus as they did not support robust replication
5
.   
Thus we set out to determine whether ISG15 can directly antagonize IBV replication in 
vitro and whether manipulation of the ISG15 conjugation pathway to increase ISG15 conjugation 
will provide increased protection from IBV infection. To address these questions we evaluated 
the effects of ISG15 on IBV replication in primary murine trachea epithelial cell cutures 
(mTEC).  Additionally, we evaluated the effects of manipulating ISG15 levels by evaluating 
influenza B virus infection both in ISG15 heterozygous mice and in a novel mouse, produced in 
the lab of Dr. Klaus-Peter Knobeloch, that expresses an enzymatically dead mutant version of 
UBP43.   
 
RESULTS 
ISG15 directly antagonizes IBV replication 
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Previous studies have determined conditions for culturing primary murine trachea 
epithelial cells at air-liquid interface in vitro to yield differentiated heterogeneous cell cultures.  
These cultures closely resemble the heterogeneous population of cells that make up the trachea 
epithelium seen in vivo and have been demonstrated to support robust influenza A virus 
replication 
14; 15
.  In order to evaluate the effects of ISG15 on IBV replication in a permissive cell 
type, we generated mTEC cultures from WT and ISG15-/- mice.  We observed no difference in 
the ability of ISG15-/- cultures to proliferate, to form tight junctions capable of maintaining air-
liquid interface, or to differentiate into ciliated cells (data not shown).  These cultures are 
responsive to type I interferon as both WT and ISG15-/- cultures induced the expression of 
ISG54 after interferon  stimulation.  Importantly, WT cultures also expressed ISG15 after 
interferon  stimulation (Figure 2.1A,B).  Both WT and ISG15-/- mTEC cultures supported 
robust IBV replication.  In non-manipulated cultures, while no difference in virus replication was 
observed at early times after infection, a small but statistically significant increase in IBV levels 
was observed in ISG15-/- cultures at late time points after infection (Figure 2.1B).  Pre-
treatement of cultures with interferon  for 24 hours prior to infection amplified this difference, 
resulting in an ~8 fold increase in virus replication in ISG15-/- cultures compared to WT cultures 
at 48 hours post infection, and an ~30 fold increase at 72 hours post infection (Figure 2.1C).  
This data shows that in a biologically relevant cell culture system, ISG15 can restrict IBV 
replication in vitro. 
 
ISG15 heterozygous mice display increased susceptibility to IBV infection 
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As our mTEC data suggested that ISG15 can directly antagonize IBV replication, we next 
wanted to evaluate whether the expression level of ISG15 affects its capacity to function as an 
antiviral protein.  To do this we evaluated the susceptibility of ISG15 heterozygous (ISG15+/-) 
mice to IBV infection.  We infected WT, ISG15-/-, and ISG15+/- mice with 1.24x10^4 PFU of 
influenza B/Yamagata/88 and either monitored mice for weight loss or sacrificed mice three days 
post infection to evaluate virus titers in the lungs.  We found that virus burden in ISG15+/- mice 
at three days post infection fell at an intermediate level, ~10 fold greater than the viral burden of 
WT mice but ~10 fold lower than the viral burden of ISG15-/- mice (Figure 2.2A).  The 
ISG15+/- mice also displayed an intermediate degree of weight loss after infection as compared 
to WT and ISG15-/- mice (Figure 2.2B).  WT mice did not lose any weight over the course of 
infection.  ISG15-/- mice began losing weight around 4-5 days post infection and lost ~25-30% 
body weight by day 8 post infection.  Whereas ISG15+/- mice did not start losing weight until 5-
6 days post infection and only lost ~5-10% body weight before regaining weight on day 8.  
These data strongly suggest that the extent of antiviral activity provided by ISG15 is directly 
correlated to its expression level. 
 
USP43
C61A/C61A
 mouse 
The ability of ISG15 to inhibit virus replication in a dose dependent manner suggests that 
manipulation of ISG15 expression levels could be a viable antiviral therapeutic strategy.  Our lab 
has previously demonstrated that the antiviral activity of ISG15 against IBV is dependent on its 
ability to form conjugates with other proteins, as UbE1L-/- mice also display increased lethality 
compared to WT mice after IBV infection 
6
.  Given these observations it stands to reason that 
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specifically increasing the amount of ISG15 conjugates might provide increased protection 
against IBV and possibly other viruses.  Thus we wanted to test whether inhibiting ISG15 
deconjugation through the inhibition of UBP43 would provide increased protection against IBV 
infection. 
 In order to test this hypothesis, Dr. Klaus-Peter Knobeloch created a novel mouse 
expressing an enzymatically dead version of UBP43.  To generate this mouse, a targeting vector 
was designed to undergo homologous recombination with the endogenous UBP43 gene such that 
the nucleotide sequence coding for the catalytic cysteine residue (amino acid number 61) was 
replace with a nucleotide sequence encoding an alanine residue (Figure 2.3A).  The vector was 
electroporated into embryonic stem cells, and cells that underwent homologous recombination 
were injected into C57BL/6 embryos.  Germline transmission of the c61a mutation and 
subsequent breeding achieved homozygous UBP43
C61A/C61A
 mice expressing an enzymatically 
dead version of UBP43 from the endogenous UBP43 locus (Figure 2.3B,C).  The UBP43c61a 
mutant appeared to retain its ability to inhibit IFN signaling as indicated both by the lack of 
interferon hypersensitivity observed after poly(I:C) infection and by the development of 
interferon refractoriness after interferon  injection in UBP43C61A/C61A  mice (Figure 2.3D,E). 
 
Susceptibility of UBP43
C61A/C61A
 mouse to influenza B virus 
To evaluate whether increasing the levels of ISG15 conjugates by UBP43 protease inactivation 
can increase antiviral protection, UBP43
C61A/C61A
 mice were infected with influenza 
B/Yamagata/88 virus.  As WT mice do not develop severe disease symptoms after IBV infection, 
we evaluated lung viral loads to assess resistance to IBV infection.  We found that three days 
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post infection the UBP43
C61A/C61A
 mice had a ~10-fold decrease in viral loads as compared to 
WT mice (Figure 2.4), suggesting that UBP43
C61A/C61A
 mice do exhibit increased resistance to 
infection 
To determine whether increasing ISGylation directly affects IBV replication in infected cells, we 
evaluated viral growth in UBP43
C61A/C61A
 mTECs.  In non-stimulated mTEC virus growth 
kinetics was similar in WT and UBP43
C61A/C61A
 mTECs though we detected a small decrease in 
virus replication at 72 hours post infection in UBP43
C61A/C61A
 mTEC (Figure 2.1C).  When 
mTEC were pretreated with interferon  for 24 hours prior to infection, we observed an increase 
in the resistance of UBP43
C61A/C61A
 cultures to IBV replication as compared to WT cultures, 
suggesting that increasing ISG15 conjugation through the inhibition of UBP43 enzymatic 
activity provides increased antiviral activity (Figure 2.1D).   
To verify that UBP43
C61A/C61A
 mTECs produce elevated ISG15 conjugates after type I 
interferon stimulation, interferon  stimulated mTEC lysates were evaluated for ISG15 
expression by western blot (Figure 2.5A).  Both WT and UBP43
C61A/C61A
 cultures expressed 
ISG15 and formed ISG15 conjugates after interferon stimulation.  Densitometry analysis showed 
that the ratio ISG15 conjugates to free ISG15 was greater in UBP43
C61A/C61A
 lysates than in WT 
lysates, suggesting that loss of UBP43 enzymatic activity does result in an accumulation of the 
pool of ISG15 conjugates (Figure 2.5B).  Interestingly, however, we observed that in addition to 
producing more ISG15 conjugates UBP43
C61A/C61A
 cultures expressed a higher level of total 
ISG15 protein than WT cultures.  Both the increased accumulation of ISG15 conjugates and the 
increased total expression of ISG15 was also observed between unstimulated WT and 
unstimulated UBP43
C61A/C61A 
 mTEC cultures.  To evaluate whether this increase in ISG15 
expression in UBP43
C61A/C61A
 mTEC was specific for ISG15 or might be reflective of a general 
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misregulation of interferon stimulated genes (ISG), we evaluated the expression levels of ISG56 
and ISG54 by western blot.  We found that both ISG56 and ISG54 were also elevated in 
UBP43
C61A/C61A
 mTEC compared to WT mTEC (Figure 2.5 A,B,C). 
We next wanted to evaluate whether there was an increase in ISG transcript levels, or 
whether this increased accumulation of ISG proteins might be a result of post-translational 
regulation of ISG protein stability.  mTEC cultures were stimulated with interferon  for 24 
hours at which point RNA was harvested from these cultures and analyzed by RT-qPCR.  
UBP43
C61A/C61A
 cultures had increased levels of ISG15 transcripts compared to WT cultures both 
at baseline and after interferon stimulation (Figure 2.6 A,B,C).  Again, this phenotype was not 
specific for ISG15, as both ISG54 and ISG56 transcript levels were also elevated in 
UBP43
C61A/C61A 
cultures compared to WT cultures. 
 
Elevated expression of ISGs and increased antiviral activity in UBP43
C61A/C61A
 mice and 
cells is dependent on ISG15 expression 
UBP43 has previously been shown to regulate interferon signalling independent of its ISG15 
deconjugation activity 
13
.  Therefore, we wanted to determine whether or not the elevated ISG 
expression in UBP43
C61A/C61A 
mTEC was dependent on the expression of ISG15.  To test this, we 
bred UBP43
C61A/C61A 
mice onto the ISG15-/- background and analyzed mTEC from these 
UBP43
C61A/C61A 
X ISG15-/- mice for ISG production after interferon stimulation.  We found that 
both the transcript and protein levels of ISG56, and ISG54 were not elevated as seen in the 
UBP43
C61A/C61A
 cells (Figure 2.5,2.6).  This suggests that the increased ISG expression in 
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UBP43
C61A/C61A
 mTEC is dependent on ISG15 and not a result of a misregulation of interferon 
signalling due to an effect of the c61a mutation on another function of UBP43.   
We next evaluated the resistance of UBP43
C61A/C61A 
X ISG15-/- mice and mTEC cultures 
to IBV infection. Three days post infection with IBV, UBP43
C61A/C61A 
X ISG15-/- mice exhibited 
elevated viral titers in their lungs compared to WT mice (Figure 2.4).  The virus burdens in these 
mice were comparable to the viral loads observed in ISG15-/- mice.  Similarly, after interferon 
pretreatment, UBP43
C61A/C61A 
X ISG15-/- mTEC cultures supported IBV replication to similar 
levels as observed in ISG15-/- mTEC cultures (Figure 2.7).  These results show that the 
increased protection from IBV observed in UBP43
C61A/C61A
 mice is dependent on ISG15. 
 
 
DISCUSSION 
Here we have shown that in a biologically relevant cell type, ISG15 can restrict influenza 
B virus replication in cell culture, suggesting that ISG15 does act as an anti-viral molecule to 
directly affect some step in the virus life cycle.  These results are consistent with our lab’s 
previous bone marrow chimera data suggesting that ISG15 expression in the radio-resistant 
compartment confers protection against IBV 
6
.  While we believe that this inhibition of IBV 
replication observed in cell culture is biologically relevant and occurs during infection in vivo, it 
is not clear whether the ~30-fold increase in virus replication in ISG15-/- mTEC completely 
accounts for the ~100- to 1000-fold increase in virus burden that is observed in ISG15-/- mice.  
Our results do not rule out a role for the immune response in contributing to the ISG15-mediated 
protection observed in vivo. 
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The intermediate levels of viral burden and weight loss observed after IBV infection in 
ISG15+/- mice relative to WT and ISG15-/- mice suggest that ISG15 protects against IBV in a 
dose dependent manner.  As far as we are aware, this is the first evidence to date to suggest that 
the level of ISG15 expression in vivo is directly correlated to the level of protection conferred 
against virus infection.  This observation has important real world implications as a study 
looking for genetic determinants of Mendelian susceptibility to mycobacterial disease discovered 
three patients who had mutations rendering them ISG15 deficient
16
.  It is unclear whether these 
ISG15 deficient individuals exhibit increased susceptibility to viral infections.  It was determined 
based on the presence of serum antibodies that these patients had been previously infected with 
influenza A virus and other common childhood viruses, and the authors suggested that this 
seropositivity demonstrated that ISG15 deficiency did not render these patients more susceptible 
to viral infection. The discovery of these ISG15 deficient individuals shows that, as in mice, 
ISG15 is not an essential gene in humans, and ISG15 deficiency does not critically 
immunocompromise an individual.  However it is not clear what “dose” of virus these 
individuals were exposed to, or whether these individuals exhibited increased disease during the 
acute infection.  ISG15-/- mice are by no means immunocompromised, and while ISG15-/- mice 
exhibit increased lethality after viral infection, a sufficient dose of virus must be given before 
this susceptibility can be observed.  Knowing that ISG15 deficiency can occur in humans, our 
results suggest that in addition to ISG15 deficiency, ISG15 heterozygosity, or trans mutations 
affecting ISG15 expression levels might also underlie increased disease susceptibility to viral 
infection. 
Ubiquitin deconjugases play an important role in controlling the ubiquitin-mediated 
regulation of biological pathways 
17
.  These deconjugating enzymes can fine-tune the specificity 
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of ubiquitination through their own specificity for target protein deconjugation.  In addition to 
displaying specificity for particular conjugated target proteins, these deconjugating enzymes also 
can display specificity for particular ubiquitin-like modifiers.  UBP43 was recently shown to 
have negligible affinity for ubiquitin compared to ISG15 
18
.  This specificity supports the 
possibility that small molecule inhibitors could potentially be developed to specifically inhibit 
UBP43.  The UBP43
C61A/C61A
 mouse represents the first insight into the effects of specifically 
inhibiting ISG15 deconjugation in vivo. 
The viability of UBP43
C61A/C61A
 mice and their lack of hydrocephalous development 
suggests that the regulation of interferon signaling through the binding of UBP43 to IFNAR2 is 
largely unaffected by the c61a mutation.  UBP43
C61A/C61A
 mice displayed decreased viral loads 
compared to WT mice 3 days after infection with IBV, and IBV replication was inhibited in 
UBP43
C61A/C61A
 mTEC compared to in WT mTEC.  These data show that increasing ISG15 
conjugation through the inhibition of UBP43 does provide increased protection against IBV.  
However, we found that in addition to increasing the ratio of ISG15 conjugates to free ISG15, 
the UBP43
C61A/C61A
 mTEC also displayed increased levels of total ISG15 compared to WT 
mTEC.  After further evaluation we found that at least a subset of other ISGs were also 
upregulated in UBP43
C61A/C61A
 mTEC.  Evaluation of UBP43
C61A/C61A
 XISG15-/- mice and 
mTEC showed that this increased ISG expression and the increased protection from viral 
infection was dependent on ISG15.  As a result of the dual effects of the UBP43c61a mutation, 
we cannot determine whether the ISG15 dependent protection is being mediated directly through 
increased ISG15 conjugation, through the increased expression of other ISGs, or though the 
combined effects of both.  Furthermore, we also cannot determine whether the observed effects 
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are due to increased ISG15 conjugation as a result of increased ISG15 expression, or increased 
ISG15 conjugation as a result of the lack of ISG15 deconjugation.  
It is important to distinguish that while the result of UBP43 inhibition is usually 
interpreted as increasing ISG15 conjugates, there is a fundamental difference between increasing 
the amount of conjugates through higher expression of ISG15 and increasing the pool of ISG15 
conjugates by preventing deconjugation.  The fate of an ISGylated protein is not well 
understood, and it is possible that the increased ISG expression observed in UBP43
C61A/C61A
 
mTEC is a result of a stress response to the accumulation of ISG15 conjugates rather than a 
direct role for ISG15 in the regulation of ISG expression.  It is interesting, however, that the two 
functions ascribed to UBP43, deconjugation of ISG15 and deconjugation-independent binding to 
IFNAR2, both have the effect of inhibiting ISG induction.  While the differences we observed in 
ISG expression in UBP43c61a mTEC were small, our results show that the mutation results in 
biologically relevant phenotypes.  The observed increase of both ISG15 conjugates and other 
ISG expression levels suggests that this UBP43 inhibition might confer increased protection 
against other ISG15 sensitive viruses, such as vaccinia, as well as additional viruses that are 
restricted by other ISGs. 
Further investigation is needed to determine whether the UBP43c61a mutation’s effect on 
ISG expression is a generalizable effect or whether this might be specific for mTEC.  While we 
noted increased ISG15 transcript expression in UBP43
C61A/C61A
 cells after interferon stimulation, 
we also observed increased expression in non-stimulated UBP43
C61A/C61A
 cells.  The actual fold 
increase in transcript expression between non-treated and interferon stimulated cultures of the 
same genotype was not different between WT and UBP43
C61A/C61A
 cells (Figure 2.6D).  mTEC 
cultures are differentiated heterogenous populations of cells.  Thus the increased ISG expression 
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could reflect an increase in the baseline expression of ISGs in all cells or an increase in the 
number of interferon responding cells in the UBP43
C61A/C61A
 cultures.  Evaluation of the number 
of ISG15 expressing cells versus the intensity at which cells express ISG15 could be performed 
by flow cytommetry analysis to address this question.  It will also be important to quantitatively 
assess ISG15 expression in other UBP43c61a cell types to evaluate how universal this phenotype 
is.   
Previous studies have reported no effect of ISGylation on interferon signaling or 
downstream ISG expression, however several aspects of these studies might have resulted in a 
role for ISG15 in ISG regulation being overlooked.  First, these studies have all been based on 
non-quantitative northern blot and western blot analyses.  The differences that we observed in 
ISG56 and ISG54 expression were small but consistent.  It is possible that this effect might be 
missed without careful normalization and quantification of northern blot experiments.  Second, 
previous experiment used relatively high doses of interferon , 100U/ml.  Our analyses were 
performed using 30U/ml.  High doses of interferon stimulation may saturate ISG induction and 
make it harder to detect a small augmentation of ISG induction mediated by ISG15.  Third, 
previous analyses of the effect of ISG15 on ISG expression were performed in embryonic 
fibroblasts.  If the effects we observed in UBP43
C61A/C61A
 mTEC are cell type specific, analysis 
of ISG15 in MEFs could have missed a biologically important role of ISG15 in regulation of 
gene expression.  The discrepancies between both our methods and results with those of the 
initial studies characterizing of the ISG15-/- and UbE1L-/- cells suggests that a quantitative 
reevaluation of the effects of ISG15 conjugation on gene expression is warranted.   
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METHODS 
Mice 
WT C57BL/6J mice originally purchased from Jackson Laboratory (Bar Harbor, ME) were bred 
in a mouse facility at Washington University in St. Louis.  Generation of ISG15-/- mice and 
backcrossing of ISG15-/- mice to the C57BL/6J background have been previously described 
19
.  
UBP43
C61A/C61A
 mice were generated as by the laboratory of Dr. Klaus-Peter Knoblach (Freeburg 
University, Germany) as described below.  The mice were backcrossed onto the C57BL/6J 
background and assessed by SNP analysis (Taconic) to by >99% C57BL/6.    
UBP43
C61A/C61A
xISG15-/- mice were generated by breeding UBP43
C61A/C61A
 mice to ISG15-/- 
mice.  
Generation of USP43
C61A/C61A 
mice 
USP18 clone (RPCI-21 332G10) was used for construction of the targeting vector (TV). A KpnI-
fragment containing the Cys61 coding region was subcloned and the codon for Cys61 5’- TGT-
3’ was mutated to 5-GCT-3’ encoding alanine. A 5´-homology arm and the 3’-homology with 
the mutation were inserted in pPNT-frt3 up- and downstream of the neomycin resistance gene 
(neo), respectively. The resulting TV was linearized and transfected into E14.1 ES cells. Positive 
ES cells were identified by Southern blotting and verified by sequencing. ES cells were injected 
into C57BL/6 morulae and germline chimeras were interbred with a FLP deleter strain to 
eliminate neo. 
Poly(I:C) and Interferon- injections 
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Mice were injected intraperitoneally with 5g of poly(I:C) (Invivogen) per gram of bodyweight 
or 1000U interferon- (Calbiochem) per gram of bodyweight.  Mice injected with poly(I:C) 
were monitored for survival.  Mice injected with interferon- were given a second injection 8 
hours after the first and interferon- levels in the serum were assessed by ELISA (PBL Assay 
Science). 
Influenza virus infections 
For influenza B virus experiments 6 to 8 week old male mice were infected intranasally with 
1.24 × 10
4
 PFU of influenza B/Yamagata/88 diluted to 25 μl total volume in PBS. Mice were 
monitored for weight loss and disease progression daily. For the determination of viral titers, 
infected mice were sacrificed on day 3 post infection and the right three lobes of the mouse’s 
lungs were collected in 1ml of PBS.  Lungs were homogenized in a Roche MagNA Lyser using 
1.0mm diameter zirconia/silia beads (BioSpec Products), and viral loads in lung homogenates 
were determined by plaque assay on MDCK cells as previously described 
5
. 
Murine tracheal epithelial cultures 
Primary mTECs were generated from the tracheas of mice as previously described 
14
. For viral 
growth curves, mTECs from WT, ISG15
-/-
, USP18
C61A/C61A
 or ISG15-/- USP18
C61A/C61A
 mice 
were either left untreated or pre-treated with 30U/ml of IFN- (PBL Assay Science) in the 
basolateral chamber. After 24 h, the basolateral chamber was washed two times with PBS and 
media with no IFN- was added back to basolateral chamber. Cells were then infected by adding 
9.0x10
5
 PFU of influenza B/Yamagata/88 in 0.1 ml of DMEM with 1% penicillin and 1% 
streptomycin (1%P/S) to the apical chamber. After 1 h the virus containing media was removed 
and the apical chamber was washed three times with 0.2 ml DMEM 1%P/S. Then 0.1ml of 
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DMEM 1% P/S was added back to apical chamber.  Cells were incubated at 37⁰ C and at various 
times apical media was collected assayed for viral titers, and replaced with 0.1ml fresh DMEM 
1%P/S to allow infection to continue.  Apical media were analyzed for virus titer by plaque assay 
on MDCK cells.  
Western Blots 
For western blot analysis, mTEC were lysed in 100-150 ul of RIPA buffer containing protease 
inhibitor (Sigma Aldrich P8340).  Lysates were analysed for ISG15 using anti-ISG15 antiserum 
20
.  Lysates were also analyzed with the following commercial antibodies, anti-ISG54 
(ThermoScientific PA3-845), anti-ISG56 (ThermoScientific PA3-846), anti- actin (Sigma AC-
74).  Western blots were analyzed by densitometry using Adobe Photoshop CS4 histogram 
analysis. 
RT-qPCR 
RNA was isolated from mTEC using Qiagen RNeasy Mini Kit.  Transcript levels in isolated 
RNA was analyzed using TaqMan One-Step RT-PCR (Applied Biosystems 4309169).  Reactions 
were run using 50 ng RNA, and the following probes were used to measure transcript levels:  
GAPDH (IDT, Mm.PT.39a.1), ISG15 (Applied Biosystems, Mm01705338_s1), ISG54 (Applied 
Biosystems, Mm00492606_m1), ISG56 (Applied Biosystems, Mm00515153_m1).  Relative 
transcript levels were determined by normalizing to GAPDH (deltaCt).  Fold differences 
(deltadeltaCt) were determined using the average deltaCt of the reference condition. 
 
Statistical analysis 
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Statistical analyses were evaluated using the Mann-Whitney U test.  Error bars in figures 
represent the SEM. 
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Figure 2.1.  ISG15 restricts influenza B virus replication in primary mTEC cultures 
(A,B) mTEC cultures generated from WT and ISG15-/- mice were left untreated or treated with 
100U/ml (A) or indicated concentration (B) of interferon  for 24 hours.  Lysates were harvested 
24 hours after interferon stimulation and protein expression was assessed by western blot.  
mTEC generated from WT, ISG15-/-,  and UBP43
C61A/C61A
 were either left untreated (C) or 
stimulated with 30U/ml of interferon  for 24 hours (D) prior to infection with 9x105 influenza 
B/Yamagata/88.  Virus titers in the apical media were assessed over time by plaque assay on 
C D 
A 
0       15         50        0   15   50 IFN β (U): 
ISG54 
β actin 
ISG15-/- WT 
WT   15-/- 
β actin 
ISG15 
B 
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MDCK cells.  Data was generated from 2 independent infections using 2 different preparation of 
mTEC, 3 replicates per infection. 
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Figure 2.2.  ISG15 heterozygous mice exhibit intermediate disease relative to WT and 
ISG15-/- mice after influenza B virus infection 
WT, ISG15-/-, and ISG15+/- were infected with 1.24x10
4
 PFU of influenza B/Yamagata/88 and 
were either monitored for weight loss (A) or sacrificed 3 days post infection to assess viral loads 
in the lungs (B).  Data in both (A) and (B) were generated from 2 independent infections.             
* p<0.05. 
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Figure 2.3. UBP43
C61A/C61A
 mice are viable, retain UBP43 inhibition of interferon signaling  
(A) Schematic of knock-in targeting strategy.  (B) Southern blot analysis UBP43 locus in WT 
and UBP43
C61A/C61A
 mice. (C) Chromatogram of UBP43 locus sequencing of cDNA isolated 
from IFN stimulated bone marrow macrophages. (D) WT, UBP43
C61A/C61A
, and UBP43-/- mice 
were injected with poly(I:C) and monitored for lethality.  (E) Serum interferon- levels of mice 
injected with interferon- as indicated were evaluated by ELISA. (This data was generated in 
the lab of Dr. Klaus-Peter Knobeloch.  Figures denotes UBP43 as USP18) 
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Figure 2.4.  UBP43c61a mutation increases protection from influenza B virus infection in 
vivo in an ISG15 dependent manner 
WT, ISG15-/-, UBP43
C61A/C61A
, or UBP43
C61A/C61A
 XISG15-/- mice were infected with 1.24x10
4
 
PFU of influenza B/Yamagata/88.  Mice were sacrificed 3 days post infection and viral loads in 
the lungs were determined by plaque assay on MDCK cells.  *** p<0.001 
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Figure 2.5.  UBP43c61a mutation increases the pool of ISG15 conjugates but also increases 
interferon stimulated gene protein levels in a conjugation dependent manner. 
mTEC generated from WT, ISG15-/-, UBP43
C61A/C61A
, or UBP43
C61A/C61A
 XISG15-/- mice were 
either left untreated or stimulated with 30U/ml of interferon  for 24 hours and protein levels 
were assessed by western blot.  2 independent interferon stimulations were performed using 1 
preparation of mTEC.  (A) One representative western blot of two.  (B) Relative protein 
expression in (A) and a duplicate experiment were assessed by densitometry analysis.  (C) 
mTEC were stimulated with 100U/ml of interferon  for 24 hours and protein levels were 
assessed by western blot. 
 
  
 60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
C 
D 
 61 
Figure 2.6.  UBP43c61a mutation causes an elevation in interferon stimulated gene 
transcript levels in an ISG15 dependent manner. 
RNA was isolated from WT, ISG15-/-, UBP43
C61A/C61A
, or UBP43
C61A/C61A
 XISG15-/- mTEC 
that were either left untreated or stimulated with 30U/ml of interferon  for 24 hours.  RNA was 
analyzed by RT-qPCR to assess interferon stimulated gene transcript levels.  Data was generated 
from 2 independent interferon stimulations using 2 different preparations of mTEC, 2-3 
replicates per experiment.  (A) Transcript levels in all conditions were assessed relative to the 
levels in untreated WT cultures.  Data in (A) is from one representative experiment.  (B) 
Transcript levels in untreated cultures relative to WT untreated cultures. (C) Transcript levels of 
interferon stimulated cultures relative to WT interferon stimulated cultures.  (D) Transcript levels 
of interferon stimulated cultures relative to levels in untreated cultures of the same genotype.  
Data from both stimulation experiments were pooled in (B-D). 
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Figure 2.7.  Increased protection against influenza B virus in UBP43
C61A/C61A
 mTEC is 
dependent on ISG15. 
mTEC generated from WT, ISG15-/-, UBP43
C61A/C61A
, or UBP43
C61A/C61A
 xISG15-/- mice were 
treated with 30U/ml of interferon  for 24 hours and then infected with 9x105 PFU influenza 
B/Yamagata/88.  Virus titers in the apical media at 48 hours post infection were assessed by 
plaque assay on MDCK cells.  Data was generated from 3 independent infections using 2 
different preparations of mTEC, 3 replicates per infection. **p<0.01 
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Chapter 3 
 
A Novel Mode of ISG15 Mediated Protection from Influenza A Virus and Sendai Virus in Mice. 
 
(Chapter 3 is being submitted, as presented here, to Journal of Virology) 
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INTRODUCTION 
During acute infection, the survival of an organism is dependent on both its ability to inhibit 
pathogen replication, thus reducing pathogen burden, and its ability to tolerate the ensuing tissue 
damage incurred both from the pathogen itself as well as from the immune response mounted 
against the pathogen.  Limiting pathogen replication and eventual pathogen clearance is 
dependent on both the innate and adaptive immune responses.  Of the many genes induced after 
viral infection, type I interferons are among the most rapidly and robustly expressed genes, and 
play a critical role in modulating the immune response to viral infections.  
After detection of viruses through pathogen recognition receptors, type I interferons are 
released from cells and subsequently bind to their cell surface receptors (IFNAR1/IFNAR2) in 
both an autocrine and paracrine fashion.  Signaling through the type I interferon receptors 
induces the expression of hundreds of genes classified as interferon stimulated genes (ISG).  A 
subset of ISGs directly inhibit different steps of virus replication, and it is through the collective 
action of these ISGs that type I interferons convert cells into what has classically been described 
as an anti-viral state 
1
.  Additionally, type I interferons play a role in the regulation of both innate 
and adaptive immune cell responses to infection 
2
.  These include their ability to induce NK cell 
activation, enhance antigen presentation activity by dendritic cells, and aid in the development 
and maintenance of CD8+ T cell memory and antibody responses.  Whether type I interferons 
play a direct role in disease tolerance is not well understood.   
 Interferon stimulated gene 15 (ISG15) is one of the most rapidly and robustly induced 
genes upon type I interferon stimulation
3; 4
.  ISG15 is an ubiquitin-like modifier containing two 
ubiquitin-like domains that share approximately 30 percent amino acid sequence identity to 
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ubiquitin.  ISG15 is expressed as a 17kD precursor protein that is proteolitically processed at its 
C-terminus to expose an LRLRGG amino acid motif through which it covalently conjugates to 
lysine residues of target proteins 
5; 6
. ISGylation of target proteins occurs through an enzymatic 
cascade similar to that of ubiquitin conjugation, involving an E1 activating enzyme, an E2 
conjugating enzyme, and an E3 ligase 
7; 8; 9; 10; 11; 12
.  Proteomic studies have identified hundreds 
of proteins as being ISGylated after interferon stimulation or capable of being ISGylated in an 
overexpression system 
13; 14
.  However, the effects of relatively few of these modifications have 
been studied and it remains unclear what the functional consequence of ISGylation is for most 
ISGylated targets. 
To date, the most striking phenotype that has been described in mice deficient in ISG15 is 
their increased susceptibility to a number of viruses, ranging from influenza viruses to herpes 
simplex virus 1 (HSV-1), Chikungunya virus (CHIKV), vaccinia virus, and Sindbis virus
15; 16; 17; 
18
.  Consequently, ISG15 has been hypothesized to protect the host from virus induced lethality 
by acting as an anti-viral molecule and directly inhibiting viral replication.  Indeed, initial studies 
into the mechanism by which ISG15 mediates protection supported a role for ISG15 in directly 
antagonizing the virus life cycle.  Our lab has shown that influenza B virus (IBV) replicates to 
100 fold greater levels in the lungs of ISG15-/- deficient mice compared to WT mice 
16
.  This 
inhibition of replication was dependent on the ability of ISG15 to form conjugates as increased 
influenza B virus replication was also seen in mice that lack the ISG15 E1 activating enzyme, 
UbE1L, and thus fail to form ISG15 conjugates 
19
.  Additionally, ISG15 has been shown to 
inhibit the replication of vaccinia virus both in vivo and in tissue culture 
18
.   
Subsequent in vitro studies have also implicated ISG15 in having a small antagonizing 
effect on the replication of influenza A virus, Sendai virus, human papillomavirus, Ebola virus, 
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and HIV-1 in tissue culture 
20; 21; 22; 23; 24; 25; 26; 27; 28
.  However, recent evidence has suggested that 
the role of ISG15 during infection is not limited to conjugation dependent inhibition of virus 
replication.  ISG15-/- but not UbE1L-/- neonatal mice are more susceptible to CHKV induced 
lethality than WT mice 
17
.  This increased lethality was not due to increased viral burden as 
similar viral loads were detected in WT, UbE1L-/-, and ISG15-/- mice.  Additionally, ISG15 was 
not found to affect CHKV replication in tissue culture.  Rather, the non-conjugated (“free”) form 
of ISG15 protected mice against CHKV by regulating cytokine expression during infection.  
Supporting this role for free ISG15 in vivo, recent reports have confirmed that extracellular free 
ISG15 can activate NK cells in vitro and augment the expression of interferon gamma in 
response to mycobacterium 
29; 30; 31
.  The ability of ISG15 to protect mice without having a direct 
effect on virus replication, and its ability to act as a cytokine, suggests that inhibition of virus 
replication in tissue culture is not the only measurement that should be used to determine 
whether ISG15 plays an important role in the host during infection. Given the newly described 
functions of free ISG15 in vivo, a more detailed characterization of the role of ISG15 in different 
viral infection models is warranted.    
It has been previously demonstrated that during influenza B virus infection ISG15 
protects the host by reducing viral burden.  In this study we sought to determine if ISG15 
protected mice by a similar mechanism of action during other respiratory virus infections.  We 
found that both ISG15-/- and UbE1L-/- mice exhibited increased susceptibility to lethality 
induced by both influenza A virus and Sendai virus infections, demonstrating that this protection 
requires ISG15 conjugation.  However, unlike influenza B virus infection, this protection did not 
appear to be mediated through the inhibition of virus replication.  We also did not observe 
significant alterations in the cytokine response or the recruitment of inflammatory cells to the 
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lungs after infection.  Together these results provide further evidence that ISG15 can protect the 
host from viral infection by mechanisms that extend beyond the regulation of viral replication.   
 
 
 
 
RESULTS 
ISG15 functions in a conjugation dependent manner to protect mice from influenza A virus 
induced lethality without altering viral loads.    
We have previously shown that ISG15 contributes to the host response against both IAV 
and IBV, as mice lacking ISG15 exhibit increased lethality after infection compared to WT mice 
16
.  ISG15 mediated protection against IBV infection is dependent upon ISG15 conjugation and 
results in the dramatic reduction in viral loads in vivo 
19
.  To determine if the protective activity 
of ISG15 during IAV infection was also dependent upon conjugation we infected WT, ISG15-/-, 
and UbE1L-/- mice with 5.0x10
3
 pfu influenza A/WSN/33 intranasally (i.n.) and monitored the 
mice for lethality.  As we have seen previously, mice lacking ISG15 displayed increased lethality 
compared to WT mice (Figure 3.1A).  This protection mediated by ISG15 appeared to be largely 
conjugation dependent, as UbE1L-/- mice also displayed increased lethality compared to WT 
mice (Figure 3.1A).  Interestingly, despite the large difference in survival, weight loss in both 
ISG15-/- and UbE1L-/- mice were similar to WT mice through nine days post infection, after 
which both the ISG15-/- and UbE1L-/- mice began to succumb to infection (Figure 3.1B).  This 
observation is strikingly different from what we have previously reported for IBV infection, 
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where increased mortality in both the UbE1L-/- and ISG15-/- mice was associated with a 
dramatic increase in weight loss as compared to WT mice 
19
.   
The increased lethality we observed in ISG15-/- mice during IBV infection was also 
accompanied by a 2-3 log increase in viral titers at days 3 and 6 post infection compared to WT 
mice, supporting the model of ISG15 acting as an antiviral molecule 
19
.  To determine if ISG15 
played a similar role during IAV infection, we next evaluated viral loads within the lungs of 
infected mice during the course of infection.  Virus could be detected in the lung 1 day post 
infection, with all three genotypes of mice displaying similar viral titers (Figure 3.1C).  Peak 
viral titers were reached by 3 days post infection, but despite the increased lethality observed in 
both the ISG15-/- and UbE1L-/- mice, we observed similar viral loads in all mice at both days 3 
and 6 post infection.  On day 8 post infection lung titers were still similar between the three 
genotypes as the mice began to clear the virus.  These results suggest that during IAV infection 
ISG15 protects the host from lethality in a conjugation dependent manner that is independent of 
its previously reported effects on viral replication.   
 
ISG15 also protects mice from Sendai virus induced lethality in a conjugation dependent 
manner with minimal impact upon viral loads. 
The observation that ISG15-/- mice succumbed to influenza A virus infection despite having no 
differences in viral loads was an unexpected result, especially given our previous findings in the 
influenza B virus model.  In order to determine if this observation was unique to IAV infection 
we wanted to evaluate the role of ISG15 conjugation in the pathogenesis of a third respiratory 
virus; therefore we infected WT, ISG15-/-, and UbE1L-/- mice i.n. with Sendai virus, a mouse 
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parainfluenza virus, and monitored them for weight loss and lethality.  As seen during IAV and 
IBV infection, ISG15 protected mice from Sendai virus induced lethality in a conjugation 
dependent manner.  In WT mice an infectious dose of 1.2x10
6 
pfu induced significant disease 
with ~25% weight loss but rarely resulted in lethality (Figure 3.2A,B).  In contrast, 70% of both 
the ISG15-/- and UbE1L-/- mice succumbed to infection by day 10 post infection.   Similar to 
what we observed during IAV infection, there was little difference in weight loss between the 
different genotypes of mice during the first 10 days of infection despite the increased lethality 
observed in both the ISG15-/- and UbE1L-/- mice (Figure 3.2B).   We next evaluated viral loads 
in the lungs of these mice during the course of Sendai virus infection.  Once again, unlike the 2-3 
log increases in viral replication that we observed during influenza B virus infection, we noted 
minimal differences in viral loads between the three genotypes during the course of Sendai virus 
infection.  In all three genotypes of mice, peak viral loads were reached at 3 days post infection, 
with no differences noted between the genotypes (Figure 3.2C).  At 6 days post infection there 
was a small, ~3-fold, increase in viral loads in the ISG15-/- and UbE1L-/- mice as compared to 
WT mice.  By day 8 post infection all three genotypes of mice had started to clear the virus, and 
we observed no difference in viral loads between WT and ISG15-/- mice, though we did detect 
increased viral burden in the UbE1L-/- mice.  Thus similar to what we observed during IAV 
infection, ISG15 protected mice from Sendai virus induced lethality in a conjugation dependent 
manner, while having a minimal impact upon viral burden over the course of infection.  
Therefore in both models, ISG15 appears to protect the host from lethality by a mechanism that 
is distinct from its role during IBV infection. 
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ISG15 does not affect Influenza A virus or Sendai virus replication in vitro 
While we did not observe a major difference between IAV or Sendai virus burden in 
ISG15-/- and WT mice, it has been previously reported that ISG15 conjugation can antagonize 
both IAV and Sendai virus replication in human cell lines.  siRNA knockdown of ISG15 or 
HERC5 in HEK293 cells resulted in increased Sendai virus replication 
23
.  Similarly, siRNA 
knockdown of ISG15 or HERC5 in A549 cells or ISG15 and UbE1L in Calu3 cells resulted in 
~5-10 fold increases in IAV replication 
20; 22
.  Given these previous findings, and the fact that we 
did see a small increase in Sendai virus titers in ISG15-/- mice at day 6 post infection, we wanted 
to more carefully evaluate whether ISG15 can directly impact viral replication in the mouse 
model.  To this end, we generated primary murine trachea epithelial cells (mTEC) from WT, 
ISG15-/-, and UbE1L-/- mice and evaluated IAV and Sendai virus growth in these cells.   
As we have previously reported that IBV replicates to higher titers in ISG15-/- mice 
compared to WT mice, we first infected mTEC with IBV to determine if these cultures could 
recapitulate the virus replication phenotype observed in vivo.  In cultures that were not pretreated 
with interferon, a small but statistically significant increase in IBV replication was observed at 
late time points in mTEC derived from ISG15-/- mice (Figure 3.3A).  This difference in IBV 
replication between ISG15-/- and WT cells increased to greater than 10 fold when the cultures 
were treated with interferon ß for 24 hours prior to infection in order to induce ISG15 expression 
and conjugation (Figure 3.3B).  Next, we assessed the replication of IAV and Sendai virus in 
mTECs lacking ISG15 or UbE1L.  In untreated mTEC both IAV and Sendai virus grew with 
similar kinetics in WT, ISG15-/- and UbE1L-/- cells (Figure 3.3C,E).  We then pretreated the 
mTEC cultures with a dose of interferon ß that induced ISG15 conjugation and resulted in ~100 
fold inhibition of virus replication at 24 and 36 hours post infection in WT mTEC.  However, 
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even after interferon stimulation we observed no difference in replication of either IAV or Sendai 
virus in any of the three genotypes of mTECs (Figure 3.3D,F).  These results, together with our 
in vivo viral titer data, suggest that unlike IBV infection in which ISG15 directly inhibits viral 
replication, during both IAV and Sendai virus infection ISG15 does not directly inhibit virus 
replication within infected cells. 
 
The loss of ISG15 does not alter the cytokine response during influenza A virus or Sendai 
virus infection. 
We have recently reported that ISG15 protects neonatal mice from Chikungunya virus induced 
lethality
17
.  In this model ISG15 downregulates the host cytokine response without affecting 
CHKV titers.  CHKV infected ISG15-/- pups exhibit a global increase in serum inflammatory 
cytokines and appear to die in a manner consistent with death by cytokine storm.  We therefore 
wanted to evaluate whether ISG15 regulation of the cytokine response to infection might be 
responsible for the increased lethality in ISG15-/- mice after IAV or Sendai virus infection.   
 We infected WT, ISG15-/- and UbE1L-/- mice with IAV and at days 3, 6, and 8 post 
infection mice were sacrificed to collect bronchoalveolar lavage fluid (BALF).  We then 
evaluated a panel of 10 proinflammatory cytokines in the BALF.  The levels of all cytokines 
evaluated peaked at 6 days post infection and were either not detectable or were greatly reduced 
by day 8 post infection (Figure 3.4A).  In a few cases there were statistically significant changes 
in cytokines levels (IL-6, RANTES, IL-12p40) however these differences were less than 2 fold 
changes between genotypes and were not seen in both the ISG15-/- and UbE1L-/- mice.  Overall, 
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no dramatic differences were observed in any BALF cytokines between WT, ISG15-/-, or 
UbE1L-/- mice at any time after IAV infection (Figure 3.4A).   
We performed a similar analysis of BALF cytokines during Sendai virus infection.  Once 
again all cytokines analyzed were induced above mock levels in all three genotypes of mice.  For 
some analytes (IL-1B, IL-6, RANTES, and IL-13) the peak response occurred at day 3, while the 
remaining cytokines peaked at day 6 post infection.  Similar to what we observed during 
influenza A virus infection, no dramatic differences were seen in any BALF cytokines between 
WT, ISG15-/-, or UbE1L-/- mice after Sendai virus infection.  Once again, in the few 
circumstances where there were statistically significant differences between groups the 
differences were less than 2 fold (Figure 3.4B).  Finally, we also evaluated interferon alpha 
levels in BALF of Sendai virus infected mice by ELISA.  The interferon alpha levels peaked at 3 
days post infection, similar to the viral titers in the lungs, and diminished over the course of 
infection.  We observed no difference in interferon alpha production in WT, ISG15-/-, or 
UbE1L-/- mice at any time after Sendai virus infection (Figure 3.4C).  Overall, the ISG15-/- and 
UbE1L-/- mice appear to produce a normal interferon and cytokine response during both 
influenza A and Sendai virus infection, unlike the global cytokine misregulation observed in 
ISG15-/- mice during CHKV infection. 
 
Similar immune cell populations are recruited to the lungs in WT, ISG15-/-, and UbE1L-/- 
mice during Sendai virus infection. 
Much of the tissue damage incurred after respiratory virus infection is believed to be a 
result of immunopathology induced in response to the virus 
32; 33
.  Characterization of highly 
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pathogenic pandemic strains of IAV have noted increased neutrophil and macrophage infiltration 
in the lungs 
34; 35
.  Additionally, a study of gene expression differences in the lung after sub-
lethal and lethal IAV infection also found that one of the strongest correlations to lethal IAV 
infection was increased neutrophil recruitment and subsequent tissue damage 
36
.  While 
neutrophils and inflammatory macrophages are necessary for control of virus replication, it is 
thought that excessive recruitment can lead to excessive damage of the lung resulting in death 
36; 
37
. We therefore next evaluated the cellular recruitment to the lungs of ISG15-/- mice during 
Sendai virus infection.  
An analysis of gross lung histopathology from infected mice revealed no obvious 
difference in the degree of inflammation between all three genotypes of mice following either 
IAV or Sendai virus infection (data not shown).  To evaluate this more carefully we first 
assessed the total number of cells that were recruited to the lung.  We infected mice with Sendai 
virus and at various times post infection we analyzed the total number of cells recovered from 
lung parenchyma digests and BALF.  We observed no difference in the total number of cells 
collected from the lung parenchyma or BALF of WT and ISG15-/- mice at any time point after 
infection, though we did find increased total cellularity in UbE1L-/- mice compared to WT mice 
at certain times (Figure 3.5A,B).  We also observed no difference in total cell numbers recruited 
to the lungs of WT and ISG15-/- mice after influenza A virus infection (data not shown).  
To more carefully analyze the makeup of the cells recruited to the lung during infection 
we performed flow cytometry on the cells isolated from the BALF and lung parenchyma during 
Sendai virus infection.  We saw an elevation of neutrophils, inflammatory monocytes, and NK 
cells over mock infected levels by day 3 post infection, but no significant differences were 
observed between WT, ISG15-/-, or UbE1L-/- mice at 3 or 6 days post infection (Figure 3.5C).  
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At day 8 post infection we did observe an increase in inflammatory monocytes in ISG15-/- lungs 
compared to WT and UbE1L-/- mice.  We observed T-cell recruitment above mock infected 
levels starting at day 6 post infection, but observed no differences in CD8+ or CD4+ T-cell 
numbers between genotypes (Figure 3.5D). We also observed similar percentages of cell types in 
BALF from WT, ISG15-/-, and UbE1L-/- mice infected with Sendai virus (data not shown).   
Overall, we observed no major differences between the three genotypes in the number or 
composition of inflammatory cells recruited to the lung after infection.   
 
During recovery from infection mice lacking ISG15 display increased pulmonary damage. 
While previous studies of respiratory virus pathogenesis have revealed that immunodeficiency 
can lead to spread of virus outside of the lung, we were unable to detect either IAV or Sendai 
virus by plaque assay in the kidney, spleen, liver, heart or brain at day 8 post infection (data not 
shown) 
38
.  Histological analysis of these organs revealed no pathology outside of the lung (data 
not shown).  Furthermore, histological evaluation of the lung epithelium at day 8 post infection 
revealed similar damage in both the ISG15-/- and UbE1L-/- mice compared to WT mice (data 
not shown).  During both IAV and Sendai virus infection the ISG15-/- and UbE1L-/- mice 
succumb to infection around days 9-10 post infection (Figures 3.1 and 3.2).  Previous 
characterization of the lung histopathology during IAV and Sendai virus infection have shown 
that at this time the airway epithelium is beginning to repair itself from the damage induced 
during the   infection 
39; 40; 41
.  We therefore hypothesized that ISG15 may play a role in lung 
repair after infection.   
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In order to evaluate the lung pathology during this healing phase we decreased the 
infectious dose of Sendai virus in order to increase the survival of ISG15-/- mice.  This reduced 
dose of Sendai virus resulted in increased survival of both the ISG15-/- and UbE1L-/- mice, with 
only 20% of the mice succumbing to the infection, while none of the WT mice died  (Figure 
3.6A).  Interestingly, at this lower dose, while WT mice began to regain body weight at day 8 
post infection, the ISG15-/- and UbE1L-/- mice were delayed in initiating weight recovery 
(Figure 3.6B).  At day 11 post infection both the ISG15-/- and UbE1L-/- mice had recovered 
only 80% of their initial body weight as compared to the 90% weight recovery observed in the 
WT mice.  An analysis of viral loads in the lungs revealed that, similar to the higher dose of 
infection peak, viral titers were observed at days 3 and 6 post infection in all genotypes, and by 
day 11 post infection all three genotypes of mice had cleared replicating virus (Figure 3.6C).  At 
both days 3 and 6 post infection we did note a small increase in viral loads (~3 fold) in ISG15-/- 
mice compared to WT mice.  The biological significance of this is unclear.  Histological 
evaluation of lungs harvested from these mice at day 11 post infection showed increased 
numbers of diseased small terminal airways in the ISG15-/- mice compared to WT mice (Figure 
3.5 D-H).  This increased disease presentation was a combination of small airways that were 
denuded of epithelium and small airways where the epithelial recovery resulted in epithelial 
hyperplasia and alveolar epithelialization.   
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DISCUSSION 
Due to its robust expression after type I interferon stimulation, ISG15 has long been 
hypothesized to contribute to the interferon mediated intracellular anti-viral response.   
Supporting this hypothesis, ISG15-/- mice have been shown to be more susceptible to viral 
infections, and a number of reports have been published showing the ability of ISG15 to 
antagonize replication of viruses in tissue culture.  One way that this inhibition has been shown 
to occur is through the ISGylation of viral and host proteins.  ISGylation of human 
papillomavirus capsid protein has been shown to inhibit the infectivity of virus that incorporates 
ISGylated capsid, and ISGylation of the influenza A virus NS1 protein has been shown to both 
inhibit its ability to associate with importin  and to affect its ability to antagonize the interferon 
response 
21; 22; 24
.  Additionally, hundreds of host proteins are also ISGylated and these 
modifications likely contribute to antagonizing the virus life cycle.  In the case of Ebola virus, 
ISG15 can inhibit VLP release by inhibiting the ubiquitin E3 ligase activity of Nedd4 
27; 28
.  It is 
not currently well understood what role ISG15 plays in the regulation of the type I interferon 
response.  Although it has been reported that ISG15 can modulate the antiviral response by 
regulating the stability of IRF3 and RIG-I after virus infection in tissue culture, evaluation of 
ISG15-/- and UbE1L-/- mice has not uncovered a role for ISGylation in the regulation of 
downstream ISG expression after type I interferon or polyI:C stimulation 
23; 42; 43; 44
.  
While there is now evidence that ISG15 can act as a protective factor during CHKV 
infection by a mechanism that does not involve inhibition of virus replication, this observation 
was found to be mediated by the unconjugated form of ISG15
17
.   Here we report a novel mode 
of ISG15 mediated protection from virus infection.  We have shown that similar to its role during 
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IBV infection, ISG15 protects mice from IAV in a conjugation dependent manner.  However 
while ISG15 is important for protecting mice from IAV induced lethality, we observed no 
difference in virus burden, suggesting that ISG15 protects mice from IAV and IBV by two 
distinct mechanisms.  And unlike its role during CHKV infection, ISG15 had no effect on 
cytokine regulation after IAV infection.  We have also shown that this mode of ISG15 mediated 
protection does not appear to be unique to IAV infection.  Through the evaluation of Sendai 
virus pathogenesis in ISG15-/- and UbE1L-/- mice, we found that ISG15 conjugation protects 
mice from Sendai virus by a mechanism that closely resembles the characteristics of ISG15-
mediated protection against IAV infection.   
While in the Sendai virus model we did detect a small increase in viral loads in ISG15-/- 
and UbE1L-/- mice compared to WT mice, these differences paled in comparison to the 
magnitude by which ISG15 restricts IBV replication.  Additionally, we observed no difference in 
IAV or Sendai virus replication in mTEC.  We believe that these results together suggest that 
ISG15 does not directly antagonize IAV or Sendai virus replication within infected cells.  Rather, 
differences in the host response may contribute to the small viral load differences observed 
during Sendai virus infection.  For example, it has been shown that ISG15 inhibits apoptosis 
through ISGylation of filamin B and that ISG15-/- peritoneal macrophages have a reduced 
phagocytic capacity 
45; 46
.  A number of viruses have been reported to induce apoptosis, and it is 
thought that in some cases this might facilitate virus spread 
47
. Either increased apoptosis or a 
decreased capacity to clear apoptotic bodies could then facilitate increase virus spread in vivo, 
and thus increased virus titers, without directly affecting the virus replication within infected 
cells.    
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It has previously been reported that ISG15 inhibits the replication of both IAV and 
Sendai virus in tissue culture 
20; 21; 22; 23
. The discrepancies between our findings and previously 
published data could reflect a difference between a primary heterogenous culture of cells and 
immortalized cell lines.  There is precedent for cell type specific effects of ISG15 on IAV 
replication, which is further supported by the fact that we did not initially detect a difference in 
IBV replication in ISG15-/- embryonic fibroblasts
16; 20
.  It is also possible that these 
discrepancies reflect a difference in the function or specificity of human and murine ISG15.  
Such species specificity has been reported with respect to the IBV NS1 protein, which can bind 
to and inhibit conjugation of human ISG15 but not mouse ISG15 
48; 49
.  It is possible that Sendai 
virus and IAV may have some capacity to inhibit anti-viral functions of murine ISG15 but not 
human ISG15.  Further studies will be needed to explain these discrepancies. 
In both IAV and Sendai virus infected mice we observed lethality at around 9 to 10 days 
post infection, a time when mice are clearing the acute viral infection, beginning to regain 
weight, and beginning to repair the airway epithelium.  By lowering the infectious dose of virus 
and allowing a significant number of the ISG15-/- mice to survive infection, we observed a 
difference in the ability of the ISG15-/- mice to recover weight, and histological examination of 
the lungs revealed increased disease in the smaller airways of the lung in the ISG15-/- mice.  It is 
not clear whether this increase in diseased airways is a result of increased damage, a defect in the 
wound repair response of ISG15-/- mice, or some combination of both.  A previous report 
evaluating disease susceptibility of different mouse strains to Sendai virus found that while 
resistant and susceptible mouse strains have dramatically different LD50 titers, little difference in 
viral loads or viral clearance were observed between mice over the course of infection
50
.  This 
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study reported that increased susceptibility to Sendai virus induced lethality seemed to correlate 
with increased damage and delayed re-epithelialization in the lung. 
Recent studies have also highlighted the importance of maintaining proper airway 
epithelial integrity in surviving IAV infection.  Mice lacking cellular inhibitor of apoptosis 2 
(cIAP2) were recently shown to exhibit increased lethality after IAV infection without any 
detected difference in virus burden or in the immune response to infection 
51
.  Rather these 
cIAP2 mice displayed increased necroptosis in the airway epithelium.   Innate lymphoid cells 
have also been reported to protect mice from IAV infection by a manner that is independent of 
controlling virus replication.  These cells secrete amphiregulin which helps to promote survival 
by increasing airway epithelial integrity 
52
.  And, increased damage to the airway epithelium was 
reported to be the main histological difference observed during lethal IAV and Streptococcus co-
infection compared to infection with either IAV or Streptococcus alone 
53
.   
Bronchiolar epithelial healing after Sendai virus infection involves the  loss of epithelial 
differentiation markers on cells, cell proliferation and migration repopulate the damaged airways, 
followed by differentiation of cells into the proper epithelial cell types 
39
.  We are currently 
investigating how ISG15 might affect this process within the lung after viral infection, but there 
is precedent for ISG15 playing a role in the process of epithelial-to-mesenchymal transition 
(EMT), an important dedifferentiation process during development and tissue wound repair.  
EMT involves a reprogramming of cellular gene expression resulting in, amongst other changes, 
a dramatic reorganization of the actin cytoskeleton and increased cell motility 
54
.  A recent 
proteomic study identified ISG15 as a protein enriched during hepatocyte growth factor induced 
EMT and while it is not clear what role ISG15 plays in this process, several studies have 
discovered functions for ISG15 that could be consistent with a role in EMT 
55
.  Epidermal 
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growth factor receptor, a protein known to be associated with EMT, is down regulated by 
overexpression of UbE1L 
56
.  Additionally, knockdown of ISG15 or UbCH8 in a breast cancer 
cell line resulted in a reorganization of the actin cytoskeleton and the decreased ability of a cell 
monolayer to close a scratch wound in tissue culture 
57
. Consistent with a potential role in either 
mitigating tissue damage or promoting tissue healing, ISG15 has also been reported to be 
induced in the brains of mice during both mechanical and genetic tissue damage recovery 
models, as well as in the brains of squirrels during periods of hibernation induced ischemia 
58; 59
.  
Ischemia induced by middle cerebral artery occlusion was found to induce ISG15 in the brains of 
mice, and both ISG15-/- and UbE1L-/- mice developed increased brain tissue damage and more 
severe neurological defects compared to WT mice as a consequence of experimentally induced 
ischemia 
60
.  Together these studies provide insight into potential pathways outside of immune 
modulation that could be regulated by ISGylation and contribute to the increased lethality we 
observe in the ISG15-/- mice during IAV and Sendai virus infection. 
ISG15 is strongly upregulated after type I interferon stimulation and viral infection, and, 
in many cases, it protects the host from viral induced morbidity and mortality.  While early 
studies demonstrated its ability to function as a direct antiviral molecule and inhibit virus 
replication, more recent studies, including this one, have revealed that ISG15 can also regulate 
additional host responses that impact upon survival.  Interestingly, while ISG15 did not inhibit 
IAV or Sendai virus replication in mice, the function of ISG15 conjugation does appear to 
correlate with the function of the type I interferons in vivo.  IFNAR-/- mice display dramatically 
elevated viral loads compared to WT mice during IBV infection
19
.  However, a number of 
studies have found either no difference or only small differences in virus replication and virus 
clearance in IFNAR-/- or STAT1-/- mice during IAV, Sendai virus, or RSV infection
19; 61; 62; 63; 
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64; 65; 66
.  Type I interferons have clearly been demonstrated to inhibit virus replication in tissue 
culture.  However the role of type I interferons during respiratory virus infections in vivo is less 
well understood, and recent findings suggest that the more important role of type I interferon 
function during these infections might be to modulate the immune response to regulate tissue 
damage and morbidity.  Similarly, our results suggest that ISG15 conjugation plays a role in 
some aspect of disease tolerance against IAV and Sendai virus infection.  It will be important in 
the future to more thoroughly evaluate how ISG15 conjugation of host proteins alters the basic 
biology of the cell, what physiological roles it plays in non-infected mice, and how these 
functions might affect disease in mice after viral infection.   
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METHODS 
Mice 
Mice were bred and maintained at Washington University School of Medicine in accordance 
with all federal and University guidelines, under specific-pathogen-free conditions.  WT 
C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME), bred and 
maintained in our facilities.  ISG15-/- mice (provided by Dr. Klaus-Peter Knobeloch, University 
Clinic Freiburg, Germany) and UbE1L-/- mice (provided by Dr. Dong-Er Zhang, University of 
California, San Diego) were generated as previously described
43
.  ISG15-/- and UbE1L-/- mice 
were fully backcrossed (>99.72% and 99.93% respectively to C57BL/6 by congenic SNP 
analysis through Taconic Laboratories (Hudson, NY).  . 
 
Viruses 
Influenza A virus.  Recombinant influenza A/WSN/33 (rWSN) virus was generated from cDNA 
as previously described 
67
. The virus was grown on MDCK cells using DMEM containing 1 
ug/ml N-acetyltrypsin (Sigma Chemicals, St. Louis, MO), 100 units/ml penicillin, and 100 ug/ml 
streptomycin (Invitrogen, Carlsbad, CA).  The cells were infected at a multiplicity of infection of 
0.01 pfu per cell, harvested 48 hrs postinfection and titered by plaque assay in MDCK cells. 
Influenza B virus.  Recominant WT influenza B/Yamagata/88 virus was grown in 10 day old 
embryonated chicken eggs and titered by plaque assay in MDCK cells.   
Sendai virus.  Sendai/52 Fushimi strain virus was purchased from ATCC.  Virus was plaque 
purified after infection of Vero cells to isolate a single clone that was then propagated in 11 day 
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old embryonated chicken eggs.  Virus from allantoic fluid was diluted in PBS and stored at -80 
degrees Celcius.   
Viral stocks were titered by plaque assay on MDCK cells for influenza virus and Vero cells for 
Sendai virus.  
 
Virus growth curves   
Murine tracheal epithelial cultures were generated from the different genotypes of mice as 
previously described 
68
.  Cells were harvest from tracheas of female mice (5 to 12-weeks old) 
and grown under media in transwells (Corning) for 7 days.  Apical media was then removed and 
the cells were grown at air-liquid interface for 2-3 weeks prior to experimentation.  For viral 
growth curves, virus was diluted in DMEM supplemented with 1% Penicillin/1% Streptomycin 
(1%P/S) to concentrations such that indicated number of pfu were administered in volumes of 
100ul.  Infections were performed by adding 100ul of virus to the apical chamber and incubating 
at 37 degrees C for 1 hour.  Virus was removed and the apical chamber was washed 3 times with 
200ul of DMEM(1%P/S).  After washing 100ul of DMEM(1%P/S) was added back to apical 
chamber.  At indicated times apical media was collected and replaced with 100ul of 
DMEM(1%P/S).  Virus titers in apical media were assessed by plaque assay on MDCK cells.  
For interferon β pretreatment conditions, indicated concentrations of interferon β (PBL Assay 
Science) were added to basolateral media.  After 24 hours, immediately prior to infection, 
basolateral media was removed and basolateral chambers were washed 2 times with PBS and 
then replaced with media containing no interferon. 
 
 86 
In vivo infections   
Mice were anesthetized using an intraperitoneal injection of a ketamine/xyline cocktail prior to 
infection.  For IAV infections, 6-8 week old female mice were infected with 5000 pfu of 
influenza A/WSN/33 virus in 25 ul PBS i.n.  For Sendai virus infections, 8-10 week old male 
mice were infected with 1.2x10
6
 pfu Sendai virus in a total volume of 30ul of PBS i.n. for figures 
3.2-3.5. For experiments performed in figure 3.6 to assess lung repair mice were infected with a 
dose (0.6-1.0x10
6
 PFU) that reduced lethality to ~20% in the ifnected ISG15-/- mice.  Weight 
loss was monitored by cage average for IAV infection and by individual mice for Sendai virus 
infection. 
 
Lung viral load assessment 
To assess lung titers, the right superior, middle, and inferior lobes were collected in 1mL of PBS.  
Lungs were homogenized in a Roche MagNA Lyser using 1.0mm diameter zirconia/silia beads 
(BioSpec Products).  Titers of lung homogenates were assessed by plaque assay using MDCK 
cells for influenza A virus and Vero cells for Sendai virus.    
 
Infiltrating cells analysis 
Bronchoalveolar lavagae analysis: BALF was collected by inserting a catheter into the trachea 
and flushing 800ul of PBS into and out of the lungs 3 times (~600ul recovered).  Lavages were 
centrifuged at 2.5rcf for 5 minutes to pellet cells.  Supernatant was collected and analyzed for 
cytokine and chemokine analysis.  Cells collected from lavages were resuspended in FACS 
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buffer (PBS, 3%BSA, 0.1% sodium azide) and cells from mice of the same genotype were 
pooled for further analysis.  Red blood cells were lysed in 200ul of RBC lysis buffer (Sigma) for 
5 minutes at room temperature.  Cells were then washed in FACS buffer, and incubated in FcR 
block for 30 minutes.  Cells were then stained in different mixes of antibodies against cell 
surface markers for 30 minutes, washed 3 times in FACS buffer, fixed in 1% formaldehyde and 
analyzed by flow cytometry (BD FACSCanto). 
 
Lung digests: For analysis of infiltrating cells in the lung parenchyma, the left lung was collected 
from a lavaged mouse.  The lung was minced with scissors and incubated in DMEM with 
350U/mL Collagenase Type I (Worthington) and 50U/mL DNAse (Worthington) for 1 hour at 
37 degrees.  Remaining tissue after digestions was crushed between the rough edge of frosted 
microscope slides.  Cells were passed through a cell strainer.  Red blood cells were lysed in 1 mL 
of RBC lysis buffer (Sigma) for 5 minutes at room temperature.  Cells were then washed with 
FACS buffer, blocked, stained and analyzed as described above for BALF cells. 
 
Antibodies 
The following antibodies were purchased from eBioscience- FITC-anti-MCH II (M5/114.15.2), 
APC-anti-B220 (RA3-682), PERCP-Cy5.5-anti-CD11b (M1/70), PERCP-Cy5.5-anti-CD3 
(145-2C11).  The following antibodies were purchased from BioLegend- FITC-anti-CD8 (53-
6.7), PE-anti-Ly6G (1A8), PE-anti-CD19 (6D5), APC-anti-CD11c (N418), Pacific Blue-anti-
Ly6c (HK1.4).  The following antibodies were purchased from BD Biosciences- PE-anti-CD4 
(GK1.5), APC-anti-NK1.1 (PK136). 
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Cytokine analysis   
BALF was collected as described above and analyzed using Bio-Rad Bio-Plex analysis 
according to manufacturer’s instructions.  Quantification of interferon alpha in BALF was 
performed using a pan-interferon alpha ELISA (PBL Assay Science).  For Sendai virus infection 
cytokine analysis, data from all time points was generated from a total of 6-8 mice collected 
from 3 separate infections, except for UbE1L-/- day 3 data which was generated from 5 mice 
over 2 infections.  Cytokine analysis of mock infected mice was generated from 2 mice of each 
genotype for days 3 and 6 post mock infection (intranasal PBS instillation), and one mouse from 
each genotype for day 8 post mock infection.  Analytes in mock infected BALF did not vary 
between genotype or day post mock infection, thus all mock values were pooled together.  For 
influenza A virus infection cytokine analysis WT and ISG15-/- data was generated from 5-6 
mice from 1-2 experiments.  UbE1L-/- data was generated from 3-4 mice from one experiment. 
Mock infection data was generated from 4-6 mice from 2-3 experiments.  No difference was 
detected between any genotype at any time points, thus all mock values were pooled together. 
 
Histology 
For lung histological analysis, mice were infected as described above and sacrificed at the 
indicated time post infection.  The right lobes were tied off with suture and excised.  The left 
lobe was inflated with 500ul formalin, or all lobes were inflated with 1.0ml of formalin.  Lungs 
were then incubated in a 50ml conical tube containing 15mL formalin.  After 36-48 hours in 
formalin, lungs were washed for at least 15 minutes in serial washes of PBS, 30% ethanol, 50% 
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ethanol, and then stored in 70% ethanol until processed for paraffin embedding, sectioning and 
staining.  Lung sections were stained with hemotoxylin and eosin and were scored blindly by a 
pathologist.   
 
Statistics 
All data were analyzed with Prizm software (GraphPad, San Diego, CA).  Statistical analyses for 
viral titers, weight loss, and cytokines were performed using Mann-Whitney U test.  Survival 
data were analyzed by the Mantel-Cox test, with death as the primary variable.  Error bars in 
figures represent the SEM. 
 
  
 90 
 
 
 
 
 
 
 
 
 
 
Figure 3.1.  ISG15 protection against influenza A virus is conjugation dependent, but  not 
anti-viral. 
WT, ISG15-/-, and UBE1L-/- mice were infected with 5.0 x 10
3
 pfu influenza A/WSN/33 i.n.  
Mice were monitored for (A)  lethality and (B) weight loss, or (C) sacrificed at the indicated  
times post infection and viral loads in the lungs were assessed by plaque assay. For viral load 
assessment, the numbers of mice analyzed per genotype at each time point are indicated in 
parentheses.  Samples were collected from 1-6 independent experiments. In (A),  * p<0.05, vs 
WT; #p<0.05 vs ISG15-/-. 
 
A B 
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Figure 3.2.  ISG15 protects against Sendai virus induced lethality by a conjugation 
dependent mechanism, but has no major effect on virus loads. 
WT, ISG15-/-, and UBE1L-/- mice were infected with 1.2x10
6
 pfu Sendai virus i.n. and 
monitored for (A)  lethality (B) weight loss or  (C) sacrificed at the indicated  times post 
infection and viral loads in the lungs were assessed by plaque assay. For viral load assessment, 
the numbers of mice analyzed per genotype at each time point are indicated in parentheses.  
Samples were collected from 2-6 experiments.  In (A) *p<0.05, vs WT.  In (B), *p<0.05, WT vs 
ISG15-/-; #p<0.05 WT vs UbE1L-/-. 
A B 
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Figure 3.3.  Influenza A and Sendai virus replication is not altered in primary tracheal 
epithelial cultures lacking ISG15 or ISG15 conjugates.    
Primary murine trachea epithelial cell cultures (mTECs) were generated from WT, ISG15-/-, or 
UBE1L-/- mice.  Cultures were either left untreated (A,C,E) or stimulated with interferon  for 
24 hours (B,D,F) before infecting with influenza B/Yamagata/88 (A,B), influenza A/WSN/33 
(C,D), or Sendai virus (E,F).  Apical media was titered by plaque assay at various times after 
infection to evaluate virus replication. Doses of interferon β and viral infectious doses were 
different for each virus: IAV: 100U/ml interferon β; 9x104 pfu.  Sendai virus: 30U/ml interferon 
β; 9x105 pfu.  IBV: 30U/ml interferon β; 9x105 pfu.  Virus growth curves were generated from 2 
independent infections performed on 2 different mTEC preparations with a total of 5-6 total 
replicates between the two infections.  * p<0.05.  
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Figure 3.4.  ISG15 does not affect cytokine production after influenza A or Sendai virus 
infection. 
WT, ISG15-/- and UBE1L-/- mice were infected with (A) 5.0x10
3
 pfu influenza A/WSN/33 or 
(B) 1.2x10
6
 pfu Sendai virus.  (A, B) At days 3, 6 and 8 post infection mice were sacrificed 
bronchoalveolar lavage fluid was analyzed for cytokines by BioRad multiplex analysis.  (C) 
Interferon- levels in BAL fluid from Sendai virus infected mice were analyzed by ELISA.  * 
p<0.05. 
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Figure 3.5.  Similar numbers and cell populations are recruited to the lungs during Sendai 
virus infection in the presence and absence of ISG15 conjugation. 
(A-C) WT, ISG15-/-, and UBE1L-/- mice were infected with 1.2x10
6
 pfu Sendai virus i.n.  Mice 
were sacrificed at 3, 6, or 8 days post infection.  Lungs were lavaged and subsequently processed 
into single cell suspensions. Single cell suspensions of digested lungs (A) and cells recovered 
from BALF (B) were analyzed for total cell number by hemocytometer count.  Cell populations 
recovered from lung digests were stained for cell surface markers and analyzed by FACS (C, D). 
* p<0.05. 
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Figure 3.6.  Infection with Sendai virus at a lower dose reveals increased weight loss and 
distal airway damage in ISG15-/- mice. 
WT, ISG15-/-, and UbE1L-/- mice were infected with 0.6-1.0x10
6 
pfu Sendai virus and were 
monitored for (A) lethality and (B)  weight loss (*p<0.05 WT vs ISG15-/-, #p<0.05 WT vs 
UbE1L-/-). (C) Viral loads in the lungs of mice were analyzed at days 3, 6, 8, and 11 post 
infection by plaque assay.  (D-H) Lungs harvested from mice infected with Sendai virus for 11 
days were fixed, sectioned, and stained with hematoxylin and eosin. (D) Representative image of 
a small airway from a mock infected mouse. (E-G) Representative images of small airways from 
a mouse infected with Sendai virus for 11 days.  Small airways were categorized into 3 principle 
states:  (E) Airways exhibiting no aberrant disease, (F) airways denuded of epithelium, and (G) 
airways with epithelial hyperplasia. (H) Stained sections were scored blindly by a pathologist by 
categorizing small airway disease status into those describe in (E-F).  An average of 52.8 small 
airways were scored per mouse (Min. 33, Max. 89, Median 46). * p<0.05.    
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Conclusions and Future Directions 
Over the course of the past 30 years, the combined efforts of many labs have characterized the 
expression of ISG15, the structure of ISG15, and both the components and biochemistry of the 
ISG15 conjugation pathway.  Yet the effects of ISG15 conjugation on target proteins remains 
poorly understood.   Most efforts to evaluate the molecular consequence of ISGylation have 
approached this question through the generation of non-ISGylatable mutant proteins, or through 
the fusion of ISG15 to the N-terminus of proteins, with minimal success.  Typically, the 
observed phenotypes have been small, and almost all effects of ISGylation have been reported to 
occur through the disruption of normal protein-protein interactions.  Also, while studies have 
observed changes in function of the ISGylated protein, most have failed to demonstrate how 
modification of a small fraction of the total protein would lead to any appreciable phenotype.  
One possible explanation for the dearth of insights into the function of ISGylation on particular 
proteins is that ISG15 mediates large effects on global cellular processes through the cumulative 
small effects on many different proteins.  However, another possibility is that previous studies 
have not examined the effects of ISGylation in biologically relevant pathways.  
In the current studies, we set out to characterize the function of ISG15 from a top-down 
approach of dissecting the mechanisms responsible for the largest phenotype discovered in 
ISG15-/- mice to date: susceptibility to viral infection.  First we evaluated the effect of ISG15 on 
influenza B virus (IBV) infection in tissue culture.  We found that ISG15 can restrict IBV 
replication in a biologically relevant cell culture system.  We then used a novel mouse expressing 
an enzymatically dead form of the ISG15 deconjugating enzyme, UBP43, to show that inhibiting 
ISG15 deconjugation increases the pool of ISG15 conjugates and increases the anti-viral 
protection mediated by ISG15.  In a separate series of studies, we characterized the pathogenesis 
 106 
of influenza A virus (IAV) and Sendai virus in ISG15-/- and UbE1L-/- mice to evaluate the role 
of ISG15 during other respiratory virus infections.  Surprisingly, we found that while ISG15 
protects mice from IAV and Sendai virus in a conjugation dependent manner, the mechanism by 
which it promotes survival of mice appears to be quite different from its role during IBV 
infection.  Little difference in viral burden between WT and ISG15-/- mice was observed in vivo, 
and no difference in IAV or Sendai virus replication was detected in tissue culture.  We also 
observed no major differences in the acute immune response after infection in ISG15-/- mice 
compared to WT mice.  Our findings suggest that ISG15-/- mice are not deficient in their ability 
to clear viral infection, but rather are more sensitive to disease induced by viral infection, either 
sustaining greater tissue damage during infection or having a decreased capacity to heal after 
infection.  
In addition to the data presented in chapters 1 and 2, preliminary data from both of these 
projects have provided a number of avenues to pursue studying the function of ISG15. 
 
ISGylation of Viral Proteins 
Some previous studies showing inhibition of virus replication by ISG15 have proposed a 
model in which ISG15 directly disrupts the virus lifecycle through ISGylation of viral proteins.  
Influenza A/NS1, influenza A/M1, and HPV capsid protein have all been shown to be ISGylated, 
and in the case of influenza A/NS1 and HPV capsid protein, ISG15 modification has been shown 
to inhibit virus replication 
1; 2; 3
.  We have also been able to demonstrate that influenza B/NS1 is 
ISGylated during infection of mTEC (Figure 4.1A).  Additionally, we have shown that influenza 
B/M1 and influenza A/M1 and A/NS1 are capable of being ISGylated in 293T cells expressing 
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the ISG15 conjugation system (data not shown).  However using brute force lysine mutagenesis, 
mass spectrometry, and other novel methods, we were unable to identify ISGylated lysine 
residues in order to generate non-ISGylatable mutant proteins.  Part of this failure was likely due 
to the ability of ISG15 to modify individual proteins on multiple lysine residues.  While 
ISGylated proteins often have only one modification, the modified species observed by western 
blot is actually a heterogeneous population of proteins modified by one ISG15 protein on 
different lysine resides.  Two reports of A/NS1 being ISGylated both found that 7-8 lysine 
residues were detected as being ISGylated, and in one of the studies all 7 lysines had to be 
mutated before NS1 was rendered non-ISGylatable 
1; 3
.   
While ISGylation of NS1 and M1 have now been reported by other labs, we also 
discovered a novel interaction between ISG15 and the influenza virus nucleoprotein protein 
(NP).  We found that in infected cells, both influenza A and influenza B NP co-
immunoprecipitated with ISG15 in a conjugation dependent interaction (Figure 4.1A,B).  
Interestingly, it was predominantly non-ISGylated NP that pulled down with ISG15.  While we 
could not detect ISGylated NP protein during infection, we were able to recapitulate this 
interaction in 293T cells expressing the ISG15 conjugation system and influenza virus NP 
(Figure 4.2A).  In this overexpression system we could detect ISGylation of NP protein (Figure 
4.2B).  As NP is known to oligomerize when expressed independent of other viral proteins, we 
believe that it is likely that the non-ISGylated NP that co-immunoprecipitates with ISG15 is 
likely being pulled down by interacting with ISGylated NP protein 
4
. However, we have not 
ruled out the possibility that NP coimmunoprecipitates with ISG15 because it is interacting with 
ISGylated host proteins.   
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It has been hypothesized that incorporation of ISGylated HPV capsid protein into HPV 
virions might affect capsid structure and thus infectivity of the virion 
2
.  In a similar model, it is 
possible that NP ISGylation alters the structure of NP oligomers and the ability of NP to cover 
and protect vRNA in vRNP complexes.  This might leave the vRNP more susceptible to RNA 
sensors.  It is not clear whether this interaction between ISG15 and NP might affect virus 
replication.  Notably, we observe this interaction during IAV infection despite observing no 
difference in IAV replication in ISG15-/- mTEC.  However, it is possible that in the case of IAV, 
other proteins, such as NS1, can compensate to inhibit the downstream effects of vRNP 
detection.  For example, A/NS1 is capable of inhibiting RIG-I, however it is not known whether 
B/NS1 is able to do the same 
5
.  It will be interesting to determine whether vRNP isolated from 
WT mTEC have ISGylated NP incorporated into them, and whether there is a difference in the 
ability of RIG-I, PKR, and other RNA sensors to bind to vRNP isolated from WT or ISG15-/- 
mTEC.  It will also be interesting to further characterize what effects this interaction between 
ISG15 and NP might have on processes not directly related to intracellular virus replication, such 
as antigen presentation, and to evaluate whether ISG15 also interacts with the NP of other 
viruses. 
 
Effects of ISG15 on Cell Transcriptome and Proteome 
As a member of the ubiquitin-like modifier family of regulatory proteins, and as one of 
the most highly induced genes after interferon stimulation, it was thought that ISG15 would play 
an important role in the regulation of interferon signaling and ISG expression. However, no 
major differences in ISG expression were observed in ISG15-/- or UbE1L-/- cells 
6; 7
.  Our 
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studies in UBP43
C61A/C61A
 cells suggest that inhibition of ISG15 deconjugation does have an 
effect on gene expression.  This effect was small but consistent, suggesting that a similar effect 
in the original studies evaluating the effect of ISG15 on ISG expression might have been 
overlooked by non-quantitative assessments of gene expression.  Furthermore, all of these 
previous studies have specifically focused on how ISG15 affects ISG expression.  There is a 
complete absence of published studies evaluating the effects of ISG15 on global gene expression. 
As a post-translational modifier, the potential effects of ISG15 are determined by the 
cellular proteome, and thus, by definition, the effects of ISG15 will be cell type specific. ISG15 
inhibition of virus replication could be mediated entirely through ISGylation of viral proteins.  
However, hundreds of host proteins are ISGylated and ISG15 interaction with Nedd4 and 
proteins in the endosomal sorting complexes required for transport (ESCRT) system has been 
shown to inhibit release of Ebola, HIV-1, and ASLV, suggesting that manipulation of host cell 
biology can also inhibit virus replication 
8; 9; 10; 11; 12
. Our IBV mTEC infection model represents 
a biologically relevant system where 24 hours of interferon stimulation converts cells into 
different states of virus permissiveness depending on the presence or absence of ISG15.  Thus it 
will be illuminating to analyze global differences in the status of these cells that might result in 
this difference in virus replication.  Cell transcriptomes could be analyzed by microarray 
analysis.  Given that ISG15 is a post-translational modifier, it might have an effect on the cellular 
proteome independent of transcriptional regulation.  Therefore it would also be informative to 
perform stable isotope labeling by amino acids in cell culture (SILAC) in order to determine how 
ISG15 might affect global protein levels in mTEC.   
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Role of ISG15 in cell death after Sendai virus infection 
As reported in Chapter 3, we observed no difference in Sendai virus replication in WT 
and ISG15-/- mTEC.  These cultures support virus replication for days after peak virus levels are 
observed in the apical media.  After 6.5 days of infection, we observed increased lactate 
dehydrogenase in the apical media of ISG15-/- mTEC compared to the apical media of WT 
mTEC (Figure 4.3A).  This indication of increased cell death was observed even though there 
was still no difference in virus production between WT and ISG15-/- cells at this late time point 
(Figure 4.3B).  When these cultures were stained for Sendai virus antigen, it was observed that 
ISG15-/- cells had a more elongated fibroblast-like morphology than WT cells (Figure 4.3C).  
These observations appear to be mediated through an ISG15 conjugation dependent mechanism 
as UbE1L-/- cultures phenocopied what was seen in ISG15-/- cultures (Figure 4.3 A-C).   
Increased cell death could potentially facilitate in increased viral spread during infection 
in vivo, which might account for the small elevation in virus burden observed ISG15-/- mice at 
some time points.  Alternatively this increased cell death might be responsible for the increased 
disease observed late during infection.  Our mTEC model provides us with a means to evaluate 
the mechanism by which ISG15 conjugation prevents cell death after Sendai virus infection.  We 
are currently working on identifying what cell death pathway is responsible for this phenotype.  
Once this has been evaluated we can return to our in vivo model to assess whether we can detect 
a similar process occurring in the distal airway epithelium and whether particular cell death 
inhibitors might protect ISG15-/- mice from increased Sendai virus induced pathology.  
Additionally, we are evaluating whether we can detect a similar phenotype after infection of 
mTEC with IAV. 
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Role of ISG15 during Sendai virus infection in vivo 
It remains unclear precisely why ISG15-/- mice are more susceptible to Sendai virus 
infection.  We did note slightly elevated titers in ISG15-/- mice compared to WT mice at some 
times after infection and there was a trend of slightly delayed virus clearance in ISG15-/- mice at 
day 8 post infection.  This makes it difficult to determine whether the increased pathology 
observed in ISG15-/- lungs is a result of increased damage from increased viral burden or a result 
of a defect in the repair response after clearance of the infection.  While we noted increased 
weight loss in ISG15-/- mice at our lower dose of Sendai virus infection, when we decreased the 
infectious dose further we observed no lethality in ISG15-/- mice and no difference in weight 
loss or weight recovery compared to WT mice (Figure 4.4).  This supports the idea that there is 
no defect in the ability of ISG15-/- mice to control and clear infection.  Rather, it appears that 
increased morbidity only occurs in ISG15-/- mice when the damage caused by infection crosses a 
certain threshold.   
While our morbidity experiments and histology analysis suggest that ISG15-/- mice are 
dying from a defect that occurs late during infection, it is important to note that we did observe 
that ISG15-/- mice exhibit ruffled fur starting at day 2-3 post infection (Figure 4.5).  Neither WT 
nor UbE1L-/- mice exhibit the ruffled fur observed in ISG15-/- mice, suggesting that this 
phenomenon results from the lack of free ISG15.  The fact that UbE1L-/- mice do not exhibit 
ruffled fur, but are still susceptible to infection, suggests that either the reason for the ruffled fur 
is inconsequential in regards to infection outcome, or that UbE1L-/- and ISG15-/- mice might be 
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susceptible to Sendai virus for different reasons.  Either way, the ruffled fur observed in ISG15-/- 
mice demonstrates that ISG15 does play a role in the early response to Sendai virus infection.  
Further evaluation is needed to determine how the response of ISG15-/- mice is different from 
WT mice.   
We have not identified any difference in inflammatory cell recruitment to the lungs, 
however, this has not been an exhaustive analysis.  It is possible that certain specific cell types 
are not recruited or functioning properly in ISG15-/- mice.  We saw no elevated recruitment of 
neutrophils or inflammatory macrophages that might suggest a mechanism for causing increased 
damage in the lung.  We also did not see major differences in T cell recruitment.  It is possible 
that while similar numbers and types of cells are recruited to the lungs, these cells might behave 
differently in the absence of ISG15.  However, our BAL cytokine analysis did not detect any 
obvious differences that might suggest a difference in the activity of the inflammatory cell 
infiltrates.   
Many increasingly esoteric hypotheses could be tested to determine how the response to 
Sendai infection in ISG15-/- mice differs from that of WT mice.  However, at this point it seems 
prudent to pursue experiments to broadly evaluate differences between WT and ISG15-/- mice 
during infection.  It has previously been reported that innate lymphoid cells can protect airway 
epithelium integrity in mice and promote survival after IAV infection without affecting viral 
burden 
13
.  This precedent reinforces the idea that we do not know whether the increased 
pathology observed in ISG15-/- mice is intrinsic to the airway epithelium or is mediated in trans 
by inflammatory cells.  To narrow down what cells might be conferring the ISG15-mediated 
protection from Sendai virus, we are currently performing bone marrow chimera experiments to 
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evaluate whether the radiosensitive or radioresistant compartments of cells are necessary and/or 
sufficient for mediating protecting through ISG15 expression.  
We are also performing microarray analysis on lung RNA harvested from mice infected 
with Sendai virus.  We have isolated total lung RNA from non-manipulated mice, and mice 
infected with Sendai virus for 3, 6, 8, and 11 days.  These samples should allow us to evaluate 
the effects of basal expression of ISG15 in non-infected mice, the early differences in gene 
expression that result in the distinct ruffled fur phenotype observed in ISG5-/- mice by day 3 post 
infection, and the environment of the healing lung at day 11 post infection. 
 
Concluding Remarks 
Because ISG15 is one of the most strongly upregulated genes after type I interferon 
stimulation, it was thought that ISG15 would play an important role in mediating the anti-viral 
state induced by type I interferons.  Surprisingly, the initial characterization of ISG15-/- mice 
found no increase in susceptiblity to LCMV and VSV infection, and no major defect in 
interferon signaling
6
.  Interestingly, similarly unexpected observations have been reported for 
ISG15’s sister diubiquitin-like modifier, FAT10.  FAT10 is an interferon  inducible diubiquitin-
like protein 
14
. While FAT10-/- cells appeared to have elevated rates of apoptosis and FAT10-/- 
mice were more sensitive to LPS than WT mice, the initial characterization of FAT10-/- mice 
revealed no other major phenotypes and no obvious defect in the immune system
15
.  A recent re-
evaluation of these mice revealed that FAT10-/- mice actually have a slightly extended life span 
and decreased adiposity compared to WT mice 
16
.  The decreased adiposity in FAT10-/- mice 
resulted from an upregulation of fatty acid metabolism genes.  This unexpected finding 
 114 
demonstrates how an interferon inducible ubiquitin-like modifier can affect basic physiology 
outside of the context of acute infection.  It will be important to further evaluate how this effect 
might factor into the response to acute infection. 
The remarkably strong protective effect of ISG15 during IBV infection has arguably been 
a double-edged sword for the ISG15 field, as it has bolstered the hypothesis that the major 
function of ISG15 is to inhibit virus replication.  However, our findings suggest that ISG15 may 
have a role in the regulation of the host response to infection outside of the immune response.  
ISG15 has been implicated in inhibiting virus budding through the regulation of a number of 
proteins that play a role in the ESCRT pathway.  How ISG15 might affect vesicular trafficking in 
non-infected host cells, and what physiological effects this might have, has not been studied.  
ISG15 has been demonstrated to be expressed during red blood cell differentiation 
17
.   While 
ISG15-/- mice are viable and have no general health defects, it is not clear how the effects of 
ISG15 on red blood cell differentiation might affect the fitness of ISG15-/- mice during acute 
respiratory infection.  ISG15 has also been reported to be expressed in the endometrium during 
pregnancy, and the overexpression of ISG15 and UbE1L have often been observed in cancer 
cells 
18; 19
. As increased lethality after virus infection remains the most robust phenotype that has 
been observed in mice, further characterization of the role of ISG15 in these in vivo infection 
models is needed.  However, to better understand the function of ISG15, it will also be important 
to re-evaluate the role of ISG15 in general homeostatic processes in vivo. 
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METHODS 
 
Mice 
Mice were bred and maintained at Washington University School of Medicine in accordance 
with all federal and University guidelines, under specific-pathogen-free conditions.  WT 
C57BL/6J mice were purchased from Jackson Laboratory (Bar Harbor, ME), bred and 
maintained in our facilities.  ISG15-/- mice (provided by Dr. Klaus-Peter Knobeloch, University 
Clinic Freiburg, Germany) and UbE1L-/- mice (provided by Dr. Dong-Er Zhang, University of 
California, San Diego) were generated as previously described.  ISG15-/- and UbE1L-/- mice 
were fully backcrossed (>99.72% and 99.93% respectively to C57BL/6 by congenic SNP 
analysis through Taconic Laboratories (Hudson, NY).  . 
 
Viruses 
Influenza A virus.  Recombinant influenza A/WSN/33 (rWSN) virus was generated from cDNA 
as previously described. The virus was grown on MDCK cells using DMEM containing 1 ug/ml 
N-acetyltrypsin (Sigma Chemicals, St. Louis, MO), 100 units/ml penicillin, and 100 ug/ml 
streptomycin (Invitrogen, Carlsbad, CA).  The cells were infected at a multiplicity of infection of 
0.01 pfu per cell, harvested 48 hrs postinfection and titered by plaque assay in MDCK cells. 
Influenza B virus.  Recominant WT influenza B/Yamagata/88 virus was grown in 10 day old 
embryonated chicken eggs and titered by plaque assay in MDCK cells.   
Sendai virus.  Sendai/52 Fushimi strain virus was purchased from ATCC.  Virus was plaque 
purified after infection of Vero cells to isolate a single clone that was then propagated in 11 day 
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old embryonated chicken eggs.  Virus from allantoic fluid was diluted in PBS and stored at -80 
degrees Celcius.   
Viral stocks were titered by plaque assay on MDCK cells for influenza virus and Vero cells for 
Sendai virus.  
 
mTEC infections 
Murine tracheal epithelial cultures were generated from the indicated genotypes of mice as 
previously described.  Cells were harvest from tracheas of female mice (5 to 12-weeks old) and 
grown under media in transwells (Corning) for 7 days.  Apical media was then removed and the 
cells were grown at air-liquid interface for 2-3 weeks prior to experimentation.  Virus was 
diluted in DMEM supplemented with 1% Penicillin/1% Streptomycin (1%P/S) to concentrations 
of 9x10
5
 pfu in 100ul of media.  Infections were performed by adding 100ul of virus to the apical 
chamber and incubating at 37 degrees C for 1 hour.  Virus was removed and the apical chamber 
was washed 3 times with 200ul of DMEM(1%P/S).  After washing 100ul of DMEM(1%P/S) was 
added back to apical chamber.  At indicated times apical media was collected and replaced with 
100ul of DMEM(1%P/S).  Virus titers in apical media were assessed by plaque assay on MDCK 
cells.  For interferon β pretreatment, 30U/ml of interferon β (PBL Assay Science) was added to 
basolateral media.  After 24 hours, immediately prior to infection, basolateral media was 
removed and basolateral chambers were washed 2 times with PBS and then replaced with media 
containing no interferon. 
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In vivo infections   
Mice were anesthetized using an intraperitoneal injection of a ketamine/xyline cocktail prior to 
infection.  8-10 week old male mice were infected intranasally with (0.6-1.0)x10
6
 pfu Sendai 
virus in a total volume of 30ul of PBS. 
Lactate dehydrogenase assay 
Lactate dehydgrogenase in apical media was assessed using CytoTox 96 NonRadioactive 
Cytotoxicity Assay (Promega).  Assay was scaled down to analyze 25 ul of sample. 
mTEC immunostaining  
mTEC were fixed by incubating in 4% formaldehyde diluted in PBS for 10 minutes.  Cells were 
permeabilized for 12 minutes in PBS, 0.2% TritonX 100, 0.1% sodium citrate.  Cells were 
blocked in PBS with 3%BSA and 3% normal goat serum for 30 minutes.  Cells were stained for 
Sendai virus antigen using anti-Sendai virus chicken serum and Alexa Fluor 488
®
 conjugated 
goat anti-chicken secondary antibody.  
 
Plasmids 
Expression plasmids were transfected into 293T cells using Lipofectamine 2000 (Life 
Technologies). 6His-ISG15(LRLRAA), 6His-ISG15(LRLRGG), HA-mUbE1L(E1), and FLAG-
mUbCM8(E2)) were described previously
20; 21
. mHERC6(E3) was described previously
22
.  
Influenza B/Lee/40 nucleoprotein and influenza A/WSN/33 nucleoprotein were cloned into 
pCMV2.0 expression plasmid. 
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Immunoprecipitations and pull-downs 
ISG15 immunoprecipitations were performed using anti-ISG15(3C2) antibody.  Anti-FLAG(M2) 
affinity resin was purchased from Sigma.  Nickel affinity resin (Qiagen) was used to pull-down 
proteins via 6-His tag.  For 293T pull-downs, 48 hours post transfection cells were lysed in RIPA 
buffer or NiNTA lysis buffer.  Cell debris was pelleted and lysate supernatant was incubated 
overnight on pull-down beads/resins at 4 degrees Celsius.  Pull-downs were washed 4 times 
using original lysis buffer.  Protein was boiled off of anti-ISG15 and Nickel affinity resins in 2x 
sample buffer.  Protein was eluted off of anti-FLAG resin using FLAG peptide.  For mTEC 
immunoprecipitations, each well of mTEC were lysed in 150ul of RIPA buffer.  Lysate from 3 
wells of each condition were pooled into the same immunoprecipitation.  The remainder of the 
mTEC immunoprecipitation protocol was identical to 293T pull-down protocol.
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Figure 4.1.  Influenza virus proteins co-immunoprecipitate with ISG15 during infection in 
mTEC. 
mTEC were generated from WT, ISG15-/-, or UbE1L-/- mice.  mTEC were pretreated with 
interferon  for 24 hours and subsequently infected with 9x105 pfu of influenza B virus (A) or 
influenza A virus (B).  36 hours post infection mTEC lysates were harvested in RIPA buffer and 
ISG15 was immunoprecipitated.  Lysates and immunoprecipitates were analyzed by western blot 
for viral protein. Arrows indicate non-modified proteins, asterisk indicates ISGylated form of 
protein. 
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Figure 4.2. Influenza virus nucleoprotein interacts with ISG15 in a conjugation dependent 
manner. 
(A) 293T cells were transfected with FLAG-tagged influenza A virus nucleoprotein or FLAG-
tagged influenza B virus expression constructs, with or without expression plasmids encoding 
the ISG15 conjugation machinery (E1, E2, E3), and HIS-tagged WT ISG15(LRLRGG) or a HIS-
tagged mutant of ISG15 incapable of undergoing conjugation ISG15(LRLRAA). 48 hours post 
transfection lysates were harvested and ISG15 was pulled down using Ni-affinity resin.  Lysates 
and pull-downs were analyzed for ISG15 and NP by western blot. 
(B) 293T cells were transfected with indicated expression constructs as in (A).  48 hours post 
transfection lysates were immunoprecipitated using anti-FLAG affinity resin, and 
immunoprecipitates were analyzed by western blot.  
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Figure 4.3.  ISG15 conjugation promotes cell survival in mTEC after Sendai virus infection 
mTEC were generated from WT, ISG15-/-, or UbE1L-/- mice.  Cultures were treated with 
30U/ml of interferon  for 24 hours and subsequently infected with 9x105 pfu Sendai virus.  (A) 
Lactate dehydrogenase levels in the apical media were assessed over the course of infection. (B) 
Sendai virus levels in the apical media at 6.5 days post infection were determined by plaque 
assay.  (C) mTEC cultures were infected with Sendai virus for 6.5 days at which point they were 
fixed and stained with anti-Sendai virus serum (white).   
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Figure 4.4.  ISG15-/- mice infected with sub-lethal dose of Sendai viruses exhibit no 
difference in weight loss compared to WT mice. 
WT and ISG15-/- mice were infected with 4x10
5
 PFU Sendai virus and monitored for weight 
loss.  Data was collected from 2 independent infections, 5 mice per infection. 
 
 
 
 126 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5.  ISG15-/- mice exhibit ruffled fur after Sendai virus infection 
WT, ISG15-/-, and UbE1L-/- mice were infected with 1.0x10
6
 PFU Sendai and pictures were 
taken daily to monitor disease.  ISG15-/- but not WT or UbE1L-/- mice exhibited a dramatic 
ruffling of fur.  Above pictures were taken on day 7 post infection, however ruffled fur in ISG15-
/- mice could be observed as early as 2-3 days post infection. 
WT
WT    
15-/-     
43      
43WT    
15-/-     
43      
43 
ISG15-/- 
UbE1L-/- 
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